Attached files
file | filename |
---|---|
EX-32.1 - China Yongxin Pharmaceuticals Inc. | v166984_ex32-1.htm |
EX-32.2 - China Yongxin Pharmaceuticals Inc. | v166984_ex32-2.htm |
EX-31.1 - China Yongxin Pharmaceuticals Inc. | v166984_ex31-1.htm |
EX-31.2 - China Yongxin Pharmaceuticals Inc. | v166984_ex31-2.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 10-Q
o
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
|
|
For
the Quarterly Period Ended September 30, 2009
|
||
OR
|
||
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
|
For
the transition period
from to
Commission
File No.: 000-26293
CHINA
YONGXIN PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
Delaware
|
20-1661391
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
Employer
Identification
Number)
|
927
Canada Court
City
of Industry, California 91748
(ADDRESS
OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)
(626)
581-9098
(COMPANY’S
TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes x No o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated
filer” and “smaller reporting company” as defined in Rule 12b-2 of the Exchange
Act.
Large
accelerated filer o
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes o No x
Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes o No o
The
registrant had 35,448,925 shares of common stock, par value $0.001 per
share, outstanding as of November 17, 2009.
CHINA
YONGXIN PHARMACEUTICALS INC.
FORM 10-Q
For
the Quarterly Period Ended September 30, 2009
INDEX
Page
|
||||||
Part I
|
Financial
Information
|
|
||||
Item 1.
|
Financial
Statements
|
3
|
||||
(a)
Unaudited Consolidated Balance Sheets as of September 30,
2009 and December 31, 2008
|
4
|
|||||
(b)
Unaudited Consolidated Statements of Income for the Three and Nine Month
Periods ended
September 30, 2009 and 2008
|
5
|
|||||
(c)
Unaudited Consolidated Statements of Cash Flows for the Nine
Month Periods ended
September 30, 2009 and 2008
|
6
|
|||||
(d)
Notes to Unaudited Consolidated Financial Statements
|
7
|
|||||
Item 2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
21
|
||||
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
29
|
||||
Item 4.
|
Controls
and Procedures
|
30
|
||||
Part II
|
Other
Information
|
|||||
Item 1.
|
Legal
Proceedings
|
30
|
||||
Item 1A.
|
Risk
Factors
|
31
|
||||
Item 2.
|
Unregistered
Sale of Equity Securities and Use of Proceeds
|
46
|
||||
Item 3.
|
Default
Upon Senior Securities
|
46
|
||||
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
47
|
||||
Item 5.
|
Other
Information
|
47
|
||||
Item
6.
|
Exhibits
|
47
|
||||
Signatures
|
48
|
2
Part I.
Financial Information
Item
1. Financial Statements
CHINA
YONGXIN PHARMACEUTICALS INC.
CONSOLIDATED
FINANCIAL STATEMENTS
September
30, 2009
(UNAUDITED)
TABLE
OF CONTENTS
Unaudited
Consolidated Balance Sheets
|
|
As
at September 30, 2009 and December 31, 2008
|
4
|
Unaudited
Consolidated Statements of Income
|
|
For
the three and nine month periods ended September 30, 2009 and
2008
|
5
|
Unaudited
Consolidated Statements of Cash Flows
|
|
For
the nine month periods ended September 30, 2009 and 2008
|
6
|
Notes
to Unaudited Consolidated Financial Statements
|
7
|
3
CHINA
YONGXIN PHARMACEUTICALS INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
AS
OF SEPTEMBER 30, 2009 AND DECEMBER 31, 2008
(UNAUDITED)
September
30, 2009
|
December
31, 2008
|
|||||||
ASSETS
|
||||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$
|
1,371,842
|
$
|
609,422
|
||||
Accounts
receivable, net
|
6,622,395
|
6,030,874
|
||||||
Notes
receivable
|
3,074,753
|
1,334,078
|
||||||
Other
receivable, net
|
2,823,356
|
356,573
|
||||||
Advances
to suppliers
|
6,576,641
|
6,186,269
|
||||||
Prepaid
expenses
|
-
|
345,686
|
||||||
Inventory,
net
|
8,747,431
|
7,864,677
|
||||||
Total
Current Assets
|
29,216,418
|
22,727,579
|
||||||
Property
and Equipment, net
|
8,733,094
|
2,680,207
|
||||||
Construction
In Progress
|
913,054
|
6,066,249
|
||||||
Intangible
Assets, net
|
47,324
|
73,687
|
||||||
Total
Assets
|
$
|
38,909,890
|
$
|
31,547,722
|
||||
LIABILITIES AND STOCKHOLDERS'
EQUITY
|
||||||||
Current
Liabilities:
|
||||||||
Accounts
payable
|
$
|
4,923,000
|
$
|
3,255,148
|
||||
Accrued
expenses & other payable
|
4,496,232
|
2,412,067
|
||||||
Advances
from customers
|
2,901,552
|
2,580,894
|
||||||
Tax
payable
|
2,183,714
|
1,240,411
|
||||||
Loans
to related parties
|
184,662
|
184,662
|
||||||
Short-term
loans payable
|
1,439,578
|
1,967,185
|
||||||
Deferred
income
|
305,340
|
273,753
|
||||||
Shares
to be issued
|
47,000
|
35,000
|
||||||
Net
liabilities of discontinued operations
|
628,837
|
628,837
|
||||||
Total
Current Liabilities
|
17,109,915
|
12,577,957
|
||||||
Long
term loan
|
1,320,300
|
1,320,390
|
||||||
Commitments
and Contingency
|
-
|
-
|
||||||
Stockholders'
Equity:
|
||||||||
Preferred
stock, $0.001 par value; 5,000,000 shares authorized;5,000,000 shares
issued and outstanding
|
5,000
|
5,000
|
||||||
Common
stock; $0.001 par value; 75,000,000 shares authorized;32,110,540 shares
issued and outstanding as of September 30, 2009 and 31,400,540
shares issued and outstanding as of December 31, 2008
|
32,111
|
31,401
|
||||||
Additional
paid in capital
|
719,536
|
615,906
|
||||||
Deferred
consulting expense - issuance of warrants
|
(11,850)
|
(72,815)
|
||||||
Prepaid
consulting - issuance of shares
|
(12,500)
|
(68,750)
|
||||||
Receivable
from a related party
|
(50,000)
|
(50,000)
|
||||||
Statutory
reserve
|
2,170,805
|
1,841,241
|
||||||
Other
comprehensive income
|
1,685,247
|
1,684,649
|
||||||
Retained
earnings
|
11,171,145
|
9,563,803
|
||||||
Non-controlling
interest
|
4,770,180
|
4,098,940
|
||||||
Total
Stockholders' Equity
|
20,479,675
|
17,649,375
|
||||||
Total
Liabilities and Stockholders' Equity
|
$
|
38,909,890
|
$
|
31,547,722
|
The
accompanying notes are an integral part of these unaudited consolidated
financial statements
4
CHINA
YONGXIN PHARMACEUTICALS INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF INCOME
FOR
THE THREE-MONTH AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2009 AND
2008
(UNAUDITED)
For
the Three-Month Periods
|
For
the Nine-Month Periods
|
|||||||||||||||
Ended
September 30,
|
Ended
September 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Net
Revenues
|
$ | 10,844,786 | $ | 15,451,100 | $ | 29,199,325 | $ | 45,025,197 | ||||||||
Cost
of Goods Sold
|
(7,685,369 | ) | (12,412,576 | ) | (21,090,595 | ) | (36,602,807 | ) | ||||||||
Gross
profit
|
3,159,417 | 3,038,524 | 8,108,730 | 8,422,390 | ||||||||||||
Operating
Expenses:
|
||||||||||||||||
Selling
expenses
|
912,094 | 858,038 | 2,495,546 | 2,582,411 | ||||||||||||
General
and administrative expenses
|
2,386,349 | 369,471 | 3,908,223 | 1,482,786 | ||||||||||||
Total
operating expenses
|
3,298,443 | 1,227,509 | 6,403,769 | 4,065,197 | ||||||||||||
Income
(Loss) From Operations
|
(139,026 | ) | 1,811,015 | 1,704,961 | 4,357,193 | |||||||||||
Other
Income (Expense):
|
||||||||||||||||
Other
income
|
1,112,309 | 683,618 | 1,906,864 | 1,517,758 | ||||||||||||
Other
expense
|
(19,981 | ) | (42,745 | ) | (40,763 | ) | (77,651 | ) | ||||||||
Interest
income (expense)
|
(6,919 | ) | (55,845 | ) | 1,066 | (282,957 | ) | |||||||||
Total
other income
|
1,085,409 | 585,028 | 1,867,166 | 1,157,150 | ||||||||||||
Operating
Income Before Income Tax and Non controlling Interest
|
946,383 | 2,396,043 | 3,572,127 | 5,514,343 | ||||||||||||
Provision
for income tax
|
(233,908 | ) | (547,088 | ) | (964,474 | ) | (1,487,230 | ) | ||||||||
Net
Income Before Non controlling Interest
|
712,475 | 1,848,955 | 2,607,653 | 4,027,113 | ||||||||||||
Non
controlling interest
|
(240,362 | ) | (191,894 | ) | (670,747 | ) | (883,775 | ) | ||||||||
Net
Income
|
472,113 | 1,657,061 | 1,936,906 | 3,143,338 | ||||||||||||
Other
Comprehensive Item:
|
||||||||||||||||
Foreign
exchange translation gain
|
18,938 | 26,258 | 598 | 862,970 | ||||||||||||
Net
Comprehensive Income
|
$ | 491,051 | $ | 1,683,319 | $ | 1,937,504 | $ | 4,006,308 | ||||||||
Earning
per share
|
||||||||||||||||
Basic
|
$ | 0.01 | $ | 0.05 | $ | 0.06 | $ | 0.10 | ||||||||
Diluted
|
$ | 0.01 | $ | 0.05 | $ | 0.06 | $ | 0.10 | ||||||||
Weighted
average number of shares outstanding
|
||||||||||||||||
Basic
|
31,667,062 | 31,291,845 | 31,288,904 | 31,150,819 | ||||||||||||
Diluted
|
32,125,923 | 31,291,845 | 31,747,765 | 31,150,819 |
The
accompanying notes are an integral part of these unaudited consolidated
financial statements
5
CHINA
YONGXIN PHARMACEUTICALS INC.
CONSOLIDATED
STATEMENT OF CASH FLOWS
FOR
THE NINE MONTH PERIODS ENDED SEPTEMBER 30, 2009 AND 2008
(UNAUDITED)
2009
|
2008
|
|||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net
Income
|
$
|
1,936,906
|
$
|
3,143,338
|
||||
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
||||||||
Provision
for bad debts
|
1,238,933
|
-
|
||||||
Issuance
of stocks and warrants for services
|
16,589
|
283,132
|
||||||
Depreciation
and amortization
|
204,737
|
228,046
|
||||||
Stocks
and warrants issued or to be issued for services
|
75,400
|
-
|
||||||
Amortization
of prepaid & deferred consulting cost
|
141,565
|
-
|
||||||
Non-controlling
interest
|
670,747
|
883,775
|
||||||
(Increase)
/ decrease in current assets:
|
||||||||
Accounts
receivable
|
(1,830,414)
|
(621,508)
|
||||||
Notes
receivable
|
(1,739,460)
|
(1,429,375)
|
||||||
Other
receivable
|
(2,464,957)
|
(506,881)
|
||||||
Advances
to suppliers
|
(390,501)
|
1,684,069
|
||||||
Prepaid
expenses
|
345,403
|
(13,633)
|
||||||
Inventory
|
(882,627)
|
(2,146,820)
|
||||||
Increase
/ (decrease) in current liabilities:
|
||||||||
Accounts
payable
|
1,484,728
|
(673,640)
|
||||||
Accrued
expenses and other payable
|
2,455,696
|
544,957
|
||||||
Tax
payable
|
942,517
|
1,575,559
|
||||||
Advances
from customers
|
320,594
|
1,012,714
|
||||||
Deferred
income
|
31,582
|
(251,873)
|
||||||
Total
Adjustments
|
620,532
|
568,522
|
||||||
Net
cash provided by operating activities
|
2,557,438
|
3,711,860
|
||||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Purchase
of property & equipment, net
|
(1,078,011)
|
(4,451,714)
|
||||||
Contribution
from minority shareholders
|
-
|
11,513
|
||||||
Net
cash used in investing activities
|
(1,078,011)
|
(4,440,201)
|
||||||
CASH
FLOWS FROM FINANCING ACTIVITIES
|
||||||||
Receipt
of loan / (payment of loan) from non-related parties
|
(752,249)
|
297,481
|
||||||
NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
727,178
|
(430,860
|
)
|
|||||
EFFECT
OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
|
35,242
|
77,505
|
||||||
CASH
AND CASH EQUIVALENTS, BEGINNING BALANCE
|
609,422
|
1,180,029
|
||||||
CASH
AND CASH EQUIVALENTS, ENDING BALANCE
|
$
|
1,371,842
|
$
|
826,674
|
||||
SUPPLEMENTAL
DISCLOSURES:
|
||||||||
Cash
paid during the year for:
|
$
|
126,707
|
$
|
223,116
|
||||
Interest
paid
|
$
|
21,158
|
$
|
983
|
||||
Income
tax paid
|
The
accompanying notes are an integral part of these unaudited consolidated
financial statements
6
CHINA
YONGXIN PHARMACEUTICALS INC.
NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – ORGANIZATION
China
Yongxin Pharmaceuticals Inc. (formerly Digital Learning Management Corporation
and Nutradyne Group, Inc.) (the “Company") was incorporated in Delaware on
February 18, 1999 under the name of FreePCSQuote. The Company through its
Chinese subsidiaries is engaged in the wholesale distribution of pharmaceutical
medicines and appliances, pharmacy retail drug stores and ginseng product
sales.
On
December 21, 2006, Changchun Yongxin Dirui Medical Co., Ltd, a Chinese
corporation ("Yongxin") and all of the shareholders of Yongxin entered into a
share exchange agreement (“Share Exchange Agreement”) with the Company. The
Share Exchange Agreement was amended on June 15, 2007 (the “Amended Exchange
Agreement”).
On
November 16, 2007, Yongxin and the Company closed on the share exchange under
the Amended Exchange Agreement. However, it was improperly documented in the
Share Exchange Agreement, that the Yongxin shareholders and the Company agreed
that the Yongxin shareholders sold and the Company acquired 100% of the equity
interests of Yongxin. On April 12, 2008, we entered into a second
amendment to the Share Exchange Agreement (“Second Amended Exchange Agreement”)
with Yongxin, effective November 16, 2007, to reflect that the Company in fact
desired to acquire from the Yongxin shareholders, and Yongxin shareholders
desired to sell to the Copmany, only 80% of the equity interest of Yongxin in
exchange for the issuance by the Company of an aggregate of 21,000,000 shares of
newly issued common stock and 5,000,000 shares of Series A Preferred Stock to
the Yongxin shareholders and/or their designees. The Series A Convertible
Preferred Stock is convertible over a 3 year period, into up to 30 million
shares of common stock.
For
accounting purposes, this transaction was accounted for as a reverse merger,
since the stockholders of Yongxin own a majority of the issued and outstanding
shares of common stock of the Company, and the directors and executive officers
of Yongxin became the directors and executive officers of the Company. This
acquisition was accounted for at historical cost in a manner similar to that in
pooling of interests method since after the acquisition, the former shareholders
of Yongxin Medical acquired majority of the outstanding shares of the Company.
The financial statements of the legal acquirer are not significant; therefore,
no pro forma financial information is submitted. The historical financial
statements are those of "Changchun Yongxin Dirui Medical Co, Inc. &
Subsidiaries".
Yongxin
was established in 1993. Yongxin is engaged in medicines wholesale and retail.
Yongxin’s operations are based in Changchun City, Jilin Province,
China.
In 2004,
Yongxin established Jilin Province Yongxin Chain Drugstore Ltd. (“Yongxin
Drugstore”) with an investment of RMB 2,500,000 (equivalent to $303,000) to
develop customer-terminal network market. In July 2005, the Company obtained the
franchise rights in Jilin Province from American Medicine Shoppe (Meixin
International Medical Chains) and by now has developed 4 chains of “Meixin
Yongxin”. As of September 30, 2009, Yongxin Drugstore has developed 20 retail
chains drug stores in the name of Yongxin Drugstore which collectively cover
4,376 M2 of
retail space throughout Changchun city in China. These drugstores sell
over-the-counter western and traditional Chinese medicines and other
medical-related products.
On March
16, 2007, Yongxin Drugstore entered into various agreements with retail drug
stores in Tianjin, established Tianjin Jingyongxin Chain Drugstore Ltd.
(“Jinyongxin Drugstore”) with an investment of $116,868, in which the Company
has the 90% ownership of the Jinyongxin Drugstore. Jinyongxin Drugstore is
located in Tianjin City, China. As of September 30, 2009, Jinyongxin Drugstore
has developed 22 retail chain drug stores with total retail space of 2,500
M2
throughout Tianjin City in China.
On May
15, 2007, Yongxin established Jilin Dingjian Natural Health Products Co., Ltd.
(“Dingjian”) with an investment of $116,868 whereby the shareholders of the
company have 90% ownership of Dingjian. Dingjian was formed under laws of the
People's Republic of China and is located in Changchun City, Jilin
Province.
On June
15 2007, Yongxin Drugstore established Baishan Caoantang Chain Drugstore Ltd.
(“Caoantang Drugstore”) with an investment of $328,430, including $144,509 in
cash and $183,921 in property and equipment, with an additional $80,000 payment
for good will to be evenly paid by Yongxin over 30 months. Caoantang Drugstore
is a wholly-owned subsidiary of Yongxin Drugstore. As of September 30, 2009,
Caoantang Drugstore operates a chain of 31 retail drugstores that collectively
cover 2,435 M2of retail
space and selling over-the-counter western and traditional Chinese medicines and
other medical-related products.
7
On May 5,
2008 the Company changed its name from Nutradyne Group, Inc to China Yongxin
Pharmaceuticals Inc.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
UNAUDITED INTERIM FINANCIAL
INFORMATION
The
accompanying unaudited consolidated financial statements have been prepared by
the Company, pursuant to the rules and regulations of the Securities and
Exchange Commission (the “SEC”) and generally accepted accounting principles for
interim financial reporting. The information furnished herein reflects all
adjustments (consisting of normal recurring accruals and adjustments) which are,
in the opinion of management, necessary to fairly present the operating results
for the respective periods. Certain information and footnote disclosures
normally present in annual consolidated financial statements prepared in
accordance with accounting principles generally accepted in the United States of
America have been omitted pursuant to such rules and regulations. These
consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and footnotes included in the Company’s Annual
Report on Form 10-K. The results of the nine months ended September 30, 2009 are
not necessarily indicative of the results to be expected for the full year
ending December 31, 2009.
BASIS OF
PRESENTATION
The
accompanying financial statements have been prepared in conformity with
accounting principles generally accepted in the United States of America. The
functional currency of our operating subsidiary, Changchun Yongxin Dirui Medical
Co., Ltd is Chinese Renminbi.
TRANSLATION
ADJUSTMENT
As of
September 30, 2009, the accounts of Yongxin were maintained, and its financial
statements were expressed, in Chinese Yuan Renminbi (“CNY”). Such financial
statements were translated into U.S. Dollars (“USD”) in accordance with
Statement of Financial Accounts Standards (“SFAS”) No. 52 (ASC 830), “Foreign
Currency Translation,” with the CNY as the functional currency. According to the
Statement, all assets and liabilities were translated at the current exchange
rate, stockholders’ equity are translated at the historical rates and income
statement items are translated at the average exchange rate for the period. The
resulting translation adjustments are reported under other comprehensive income
in accordance with SFAS No. 130 (ASC 220), “Reporting Comprehensive Income” as a
component of shareholders’ equity.
USE OF
ESTIMATES
The
preparation of financial statements in conformity with generally accepted
accounting principles in the United States (“GAAP”) requires management to make
certain estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates. Significant estimates include collectability of accounts
receivable, accounts payable, sales returns and recoverability of long-term
assets.
PRINCIPLES OF
CONSOLIDATION
The
consolidated financial statements include the accounts of China Yongxin
Pharmaceuticals Inc. and its subsidiaries collectively referred to within as the
“Company”. All material inter-company accounts, transactions and
profits have been eliminated in consolidation.
NON-CONTROLLING
INTEREST
The
Company owns 90% ownership interest in Jinyongxin
Drugstore and Dingjian. The remaining 10% interest in each of the
entities is owned by third parties. As at September 30, 2009, minority interest
in Jinyongxin Drugstore and Dingjian amounted to $32,249 compared to $20,286 as
at December 31, 2008. The Company acquired 80% of Yongxin. The
remaining 20% represents minority interest amounting to $4,737,931 as at
September 30, 2009 compared to $4,078,654 as at December 31,
2008.
8
ACCOUNTS
RECEIVABLE
The
Company maintains reserves for potential credit losses on accounts receivable.
Management reviews the composition of accounts receivable and analyzes
historical bad debts, customer concentrations, customer credit worthiness,
current economic trends and changes in customer payment patterns to
evaluate the adequacy of these reserves. Reserves are recorded primarily on a
specific identification basis. As of September 30, 2009 and December 31, 2008,
allowance for doubtful debts amounted to $1,372,350 and $112,452,
respectively.
ADVANCES TO SUPPLIERS
The
Company advances to certain vendors for purchase of its material. The
advances to suppliers are interest free and unsecured. As of September 30, 2009
and December 31, 2008, advance to suppliers amounted to $6,576,641 and
$6,186,269, respectively.
INVENTORIES
Inventories
are valued on a lower of weighted average cost or market
basis. Inventory includes product cost, inbound freight,
warehousing costs and vendor allowances not included as a reduction of
advertising expense. The management compares the cost of inventories with the
market value and allowance is made for writing down their inventories to market
value, if lower. Work in process inventories include the cost of raw materials
and outsource processing fees.
PROPERTY AND
EQUIPMENT
Property
and equipment are recorded at cost. Depreciation is computed using the
straight-line method over useful lives ranging from 5 to 10 years. Expenditures
for maintenance and repairs are charged to earnings as incurred; additions,
renewals and betterments are capitalized. When property and equipment are
retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in
operations. Assets held under capital leases are recorded at the lesser of the
present value of the future minimum lease payments or the fair value of the
leased property. Expenditures for maintenance and repairs are charged to
operations as incurred. Depreciation of property and equipment is provided using
the straight-line method for substantially all assets with estimated lives
of:
Buildings
|
20
years
|
Infrastructures
and leasehold improvements
|
10
years
|
Equipment
(including electronic facilities, sports, education and recreation
facilities)
|
10
years
|
Automobiles
|
10
years
|
Furniture
and fixtures
|
5
years
|
Computer hardware and
software
|
5
years
|
IMPAIRMENT OF LONG-LIVED
ASSETS
Effective
January 1, 2002, the Company adopted Statement of Financial Accounting Standards
No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS
144”) (ASC 360), which addresses financial accounting and reporting for the
impairment or disposal of long-lived assets and supersedes SFAS No. 121,
“Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
be Disposed Of,” and the accounting and reporting provisions of APB Opinion No.
30, “Reporting the Results of Operations for a Disposal of a Segment of a
Business.” The Company periodically evaluates the carrying value of long-lived
assets to be held and used in accordance with SFAS 144 (ASC 360). SFAS 144 (ASC
360) requires impairment losses to be recorded on long-lived assets used in
operations when indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets are less than the assets’
carrying amounts. In that event, a loss is recognized based on the amount by
which the carrying amount exceeds the fair market value of the long-lived
assets. Loss on long-lived assets to be disposed of is determined in a similar
manner, except that fair market values are reduced for the cost of
disposal.
9
REVENUE
RECOGNITION
The
Company’s revenue recognition policies are in compliance with Staff Accounting
Bulletin (“SAB”) 104 (ASC 605). Sales revenue is recognized at the date of
shipment to customers when a formal arrangement exists, the price is fixed or
determinable, the delivery is completed, no other significant obligations of the
Company exist and collectability is reasonably assured. The Company recognizes
revenue net of an allowance for estimated returns, at the time the merchandise
is sold or services performed. The allowance for sales returns is estimated
based on the Company’s historical experience. Sales taxes are presented on a net
basis (excluded from revenues and costs). Payments received before all of the
relevant criteria for revenue recognition are satisfied are recorded as unearned
revenue.
FAIR VALUE OF FINANCIAL
INSTRUMENTS
Statement
of Financial Accounting Standard No. 107 (ASC 825), Disclosures about fair value
of financial instruments, requires that the Company disclose estimated fair
values of financial instruments. The carrying amounts reported in the statements
of financial position for current assets and current liabilities qualifying as
financial instruments are a reasonable estimate of fair value.
STOCK BASED
COMPENSATION
Effective
January 1, 2006, the Company adopted Statement No. 123R (ASC 718),
Share-Based Payment (SFAS 123R), which requires companies to measure and
recognize compensation expense for all stock-based payments at fair value. SFAS
123R is being applied on the modified prospective basis. Prior to the adoption
of SFAS 123R, the Company accounted for its stock-based compensation plan s
under the recognition and measurement principles of Accounting Principles Board
(APB) Opinion No. 25, Accounting for Stock Issued to Employees, and
related interpretations, and accordingly, recognized no compensation expense
related to the stock-based plans. Under the modified prospective approach, SFAS
123R applies to new awards and to awards that were outstanding on
January 1, 2006 that are subsequently modified, repurchased or
cancelled.
BASIC AND DILUTED EARNINGS
PER SHARE
Earnings
per share are calculated in accordance with the Statement of Financial
Accounting Standards No. 128 (SFAS No. 128) (ASC 260), “Earnings per share”.
SFAS No. 128 (ASC 260) superseded Accounting Principles Board Opinion No.15 (APB
15). Net income (loss) per share for all periods presented has been restated to
reflect the adoption of SFAS No. 128. Basic earnings per share are computed by
dividing net income by the weighted average number of common shares outstanding
during the period. Diluted earnings per share are computed by dividing net
income by the weighted average number of common shares and dilutive common
equivalent shares (restricted stock awards and stock options) outstanding during
the period. Weighted average number of common shares was calculated in
accordance with the Statement of Financial Accounting Standards No. 141R (SFAS
No. 141R) (ASC 805), “Business Combinations”. Basic and diluted earning per
share was $0.01 and $0.06 for the three and nine month periods ended September
30, 2009, respectively. Basic and diluted earning per share was $0.05 and $0.10
for the three and nine month periods ended September 30, 2008,
respectively.
SEGMENT
REPORTING
Statement
of Financial Accounting Standards No. 131 ("SFAS 131") (ASC 250), "Disclosure
about Segments of an Enterprise and Related Information" requires use of the
"management approach" model for segment reporting. The management
approach model is based on the way a company's management organizes segments
within the company for making operating decisions and assessing performance.
Reportable segments are based on products and services, geography, legal
structure, management structure, or any other manner in which management
disaggregates a company. The Company allocates its resources and assesses the
performance of its sales activities based upon its products and services (see
Note 19).
10
RECENT ACCOUNTING
PRONOUNCEMENTS
In June
2009, the FASB issued ASC 105 (previously SFAS No. 168, The FASB Accounting
Standards Codification and the Hierarchy of Generally Accepted Accounting
Principles ("GAAP") - a replacement of FASB Statement No. 162), which will
become the source of authoritative accounting principles generally accepted in
the United States recognized by the FASB to be applied to nongovernmental
entities. The Codification is effective in the third quarter of 2009, and
accordingly, the Quarterly Report on Form 10-Q for the quarter ending
September 30, 2009 and all subsequent public filings will reference the
Codification as the sole source of authoritative literature. The Company does
not believe that this will have a material effect on its consolidated financial
statements.
In June
2009, the FASB issued ASC 855 (previously SFAS No. 165, Subsequent Events),
which establishes general standards of accounting for and disclosures of events
that occur after the balance sheet date but before the financial statements are
issued or available to be issued. It is effective for interim and annual periods
ending after June 15, 2009. There was no material impact upon the adoption of
this standard on the Company’s consolidated financial statements.
In
June 2009, the FASB issued ASC 860 (previously SFAS No. 166,
“Accounting for Transfers of Financial Assets”) , which requires additional
information regarding transfers of financial assets, including securitization
transactions, and where companies have continuing exposure to the risks related
to transferred financial assets. SFAS 166 eliminates the concept of a
“qualifying special-purpose entity,” changes the requirements for derecognizing
financial assets, and requires additional disclosures. SFAS 166 is effective for
fiscal years beginning after November 15, 2009. The Company does not
believe this pronouncement will impact its financial statements.
In
June 2009, the FASB issued ASC 810 (previously SFAS No. 167) for
determining whether to consolidate a variable interest entity. These amended
standards eliminate a mandatory quantitative approach to determine whether a
variable interest gives the entity a controlling financial interest in a
variable interest entity in favor of a qualitatively focused analysis, and
require an ongoing reassessment of whether an entity is the primary beneficiary.
These amended standards are effective for us beginning in the first quarter of
fiscal year 2010 and we are currently evaluating the impact that adoption will
have on our consolidated financial statements.
In August
2009, the FASB issued Accounting Standards Update (“ASU”) 2009-05, which amends
ASC Topic 820, Measuring Liabilities at Fair Value, which provides additional
guidance on the measurement of liabilities at fair value. These amended
standards clarify that in circumstances in which a quoted price in an active
market for the identical liability is not available, we are required to use the
quoted price of the identical liability when traded as an asset, quoted prices
for similar liabilities, or quoted prices for similar liabilities when traded as
assets. If these quoted prices are not available, we are required to use another
valuation technique, such as an income approach or a market approach. These
amended standards are effective for us beginning in the fourth quarter of fiscal
year 2009 and are not expected to have a significant impact on our consolidated
financial statements.
NOTE
3 –OTHER RECEIVABLE
Other
receivables as of September 30, 2009 and December 31, 2008, are summarized as
follows. The receivables are interest free, unsecured, and due on
demand.
September 30,
2009
|
December 31,
2008
|
|||||||
Advance
to employees
|
$ | 52,961 | $ | 92,368 | ||||
Advances
to store employees
|
41,350 | 2,685 | ||||||
Advances
to third parties
|
104,885 | 93,364 | ||||||
Rent
receivable
|
79,218 | 79,223 | ||||||
Deposits
|
25,796 | 7,619 | ||||||
Sponsorship
from customers
|
687,956 | - | ||||||
Others
|
794,112 | 81,314 | ||||||
Total
|
$ | 2,823,356 | $ | 356,573 |
NOTE
4 – PREPAID EXPENSES
The
balance of Company prepaid expenses as of September 30, 2009 and December 31,
2008 comprised of the following:
September 30,
2009
|
December 31, 2008
|
|||||||
Prepaid
rent
|
$ | - | $ | 273,484 | ||||
Other
prepaid expenses
|
- | 72,202 | ||||||
Total
|
$ | - | $ | 345,686 |
11
NOTE
5 – INVENTORIES
As of
September 30, 2009 and December 31, 2008, inventory consisted of the
following:
September 30,
2009
|
December 31,
2009
|
|||||||
Raw
Materials
|
$ | 81,762 | $ | 342,832 | ||||
Finished
Goods
|
8,725,728 | 7,521,845 | ||||||
Total
inventory
|
8,807,490 | 7,864,677 | ||||||
Reserve
for obsolescence
|
(60,059 | ) | - | |||||
Net
inventory
|
$ | 8,747,431 | $ | 7,864,677 |
NOTE
6 - PROPERTIES AND EQUIPMENT
As of
September 30, 2009 and December 31, 2008 the property and equipment of the
Company consisted of the following:
September 30,
2009
|
December 31,
2008
|
|||||||
Office
furniture and fixtures
|
$ | 922,165 | $ | 998,730 | ||||
Vehicles
|
392,557 | 441,921 | ||||||
Buildings
|
8,459,550 | 2,085,988 | ||||||
Total
property and equipment
|
9,774,272 | 3,526,639 | ||||||
Less:
Accumulated depreciation
|
(1,041,178 | ) | (846,432 | ) | ||||
Net
value of property and equipment
|
$ | 8,733,094 | $ | 2,680,207 |
The
Company had depreciation expense of $198,687 and $209,195 for the nine month
periods ended September 30, 2009 and 2008.
NOTE
7 CONSTRUCTION IN PROGRESS & SOFTWARE
DEVELOPMENT
As of
September 30, 2009 and December 31, 2008, construction in progress, representing
Infrastructures improvement and software development, amounted to $913,054 and
$6,066,249, respectively. The amount of capitalized interest included
in construction in progress as of September 30, 2009 and December 31, 2008 is $
122, 429 and $311,702, respectively. The constructions were finished
in end September and were transferred to fixed assets.
As of
September 30, 2009 and December 31, 2008, the construction in progress of the
Company consisted of the following:
September 30,
2009
|
December 31, 2008
|
|||||||
Infrastructures
improvement
|
$ | - | $ | 4,841,430 | ||||
Capitalized
interest
|
- | 311,702 | ||||||
Total
infrastructures improvement
|
- | 5,754,547 | ||||||
Software
development
|
913,054 | 913,117 | ||||||
Total
construction in progress
|
$ | 913,054 | $ | 6,066,249 |
NOTE
8- INTANGIBLE ASSETS
As of
September 30, 2009 and December 31, 2008, the intangible assets of the Company
consisted of the following:
12
September 30, 2009
|
December 31, 2008
|
|||||||
Trade
mark
|
$ | 1,174 | $ | 1,174 | ||||
Software
|
86,304 | 109,293 | ||||||
Total
intangible assets
|
87,478 | 110,467 | ||||||
Less:
Accumulated amortization
|
(40,154 | ) | (36,780 | ) | ||||
Net
value of intangible assets
|
$ | 47,324 | $ | 73,687 |
The
amortization expense for the nine month periods ended September 30, 2009 and
2008 amounted to $6,050 and $18,851, respectively.
The
amortization expenses for intangible assets for next five years after September
30, 2009 are as follows:
September
30, 2010
|
$ | 19,905 | ||
September
30, 2011
|
19,211 | |||
September 30, 2012
|
8,208 | |||
Total
|
$ | 47,324 |
NOTE
9 - ACCRUED EXPENSES AND OTHER PAYABLE
The other
payable represents the deposits made by the sales representatives and sales
distributors for the right to sale products for the Company. Other
payables and accrued expenses consist of the following as of September 30, 2009
and December 31, 2008:
September 30, 2009
|
December 31, 2008
|
|||||||
Accrued
compensation
|
$ | 1,004,627 | $ | 998,824 | ||||
Accrued
rent expense
|
204,819 | 247,573 | ||||||
Accrued
professional fees
|
654,506 | 60,806 | ||||||
Accrued
litigation
|
1,359,906 | 311,685 | ||||||
Accrued
interest
|
25,069 | 78,473 | ||||||
Accrued
payable to other companies
|
1,066,944 | 435,135 | ||||||
Accrued
education& employee funds
|
70,569 | 29,088 | ||||||
Other
accrued expense
|
- | 48,564 | ||||||
Accrued
warrant expense
|
- | - | ||||||
Sales
agent deposits
|
109,792 | 84,668 | ||||||
Other
payable
|
- | 117,251 | ||||||
Total
|
$ | 4,496,232 | $ | 2,412,067 |
NOTE
10 - ADVANCE FROM CUSTOMERS
The
advances from customers amounted to $2,901,552 and $2,580,894, respectively as
of September 30, 2009 and December 31, 2008, represent the deposits made by
customers to purchase inventory from the Company.
NOTE
11 - DEFERRED INCOME
A portion
of the Company’s net revenue is derived directly from government-sponsored
healthcare programs, and the Company is therefore subject to government
regulations on reimbursement on the sales made through the healthcare programs.
The Jilin Province Social Insurance Bureau and Changchun City Insurance Bureau
reimburse 90% of the sales that the Company’s pharmacy retail stores made
through the healthcare program networks in the following month, and retain 10%
of the sales until the following year. The amount will be repaid proportionally
based on the level of evaluation made by the Insurance Bureaus in the following
year. The Company classified the 10% of sales that made through the healthcare
program networks as deferred income as the collectability of the sales is
uncertain. As of September 30, 2009 and December 31, 2008, the Company has
deferred income of $305,340 and $273,753, respectively.
13
NOTE
12 - SHARES TO BE ISSUED
The
Company classifies all amounts, against which shares have not been issued, as
shares to be issued. Once the Company issues shares, the amounts are classified
as Common stock. As of September 30, 2009 the Company has total 500,000 shares
to be issued with balance of $35,000 pursuant to an agreement with a software
consultant entered into by the Company in 2005, and the amount is included in
the accrued expenses.
During
the nine month period ended September 30, 2009 the Company entered into an
agreement with an investor relation firm for services. The term of the services
is one year and the Company is obligated to issue 600,000 shares to the investor
relation firms. As of September 30, 2009, only 300,000 shares were issued to the
investor relation firm and the balance are still to be issued. The Company has
recorded the fair market value of the 300,000 shares of $36,000 as shares to be
issued. The unamortized portion of the fee of $24,000 has been recorded as a
contra amount and netted out.
NOTE
13 -TAXES PAYABLE
Tax
payable comprised of the following taxes as of September 30, 2009 and December
31, 2008:
September
30, 2009
|
December
31, 2008
|
|||||||
VAT
|
$ | 4,561 | $ | 14,247 | ||||
Business
Tax
|
94,785 | 166,817 | ||||||
City
Construction Tax
|
6,708 | 6,660 | ||||||
Education
Tax
|
5,378 | 5,357 | ||||||
Income
Tax
|
2,071,363 | 1,046,004 | ||||||
Others
|
919 | 1,326 | ||||||
Total
|
$ | 2,183,714 | $ | 1,240,411 |
The
Company is registered in the State of Delaware and has operations in primarily
two tax jurisdictions; the PRC and the United States. For certain operations in
the US, the Company has incurred net accumulated operating losses for income tax
purposes. The Company believes that it is more likely than not that these net
accumulated operating losses will not be utilized in the future. Therefore, the
Company has provided full valuation allowance for the deferred tax assets
arising from the losses at these locations as of September 30, 2009.
Accordingly, the Company has no net deferred tax assets.
The
provision for income taxes from continuing operations on income consists of the
following for the nine months periods ended September 30, 2009 and
2008:
2009
|
2008
|
|||||||
Current
income tax expense
|
||||||||
US
Federal
|
- | - | ||||||
US
State
|
- | - | ||||||
PRC current income tax
expense
|
$ | 964,474 | $ | 1,487,230 | ||||
Total Provision for Income
Tax
|
$ | 964,474 | $ | 1,487,230 |
The
following is a reconciliation of the provision for income taxes at the U.S.
federal income tax rate to the income taxes reflected in the Statement of
Operations:
2009
|
2008
|
|||||||
Tax
expense (credit) at statutory rate - federal
|
34 | % | 34 | % | ||||
State
tax expense net of federal tax
|
6 | % | 6 | % | ||||
Changes
in valuation allowance
|
(40 | )% | (40 | )% | ||||
Foreign
income tax - PRC
|
25 | % | 25 | % | ||||
Exempt
from income tax
|
- | - | ||||||
Temporary
difference
|
2 | % | 2 | % | ||||
Tax expense at actual rate
|
27 | % | 27 | % |
14
United States of
America
The
Company has significant income tax net operating losses (“NOL”) carried forward
from prior years. Due to the change in ownership of more than fifty percent, the
amount of NOL which may be used in any one year will be subject to a restriction
under section 382 of the Internal Revenue Code. Due to the uncertainty of the
realizability of the related deferred tax assets of $5,224,976, a reserve equal
to the amount of deferred income taxes has been established at September 30,
2009.
People’s Republic of China
(“PRC”)
Pursuant
to the PRC Income Tax Laws, the Company's subsidiary is generally subject to
Enterprise Income Taxes ("EIT") at a statutory rate of 25%,
The
following table sets forth the significant components of the provision for
income taxes for operation in PRC as of September 30, 2009 and
2008.
2009
|
2008
|
|||||||
Net
taxable income
|
$ | 5,495,268 | $ | 5,916,664 | ||||
Income tax @ 27%
|
$ | 964,474 | $ | 1,487,230 |
NOTE
14 - SHORT-TERM LOANS PAYABLE
The
Company had loans payable amounting to $1,439,578 as of September 30, 2009 and
$1,967,185 as of December 31, 2008. The loans are secured by personal properties
of a main shareholder of the Companies. The loans payable at September 30, 2009
comprised of the following:
September 30,
2009
|
December 31,
2008
|
|||||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
$ | 88,020 | $ | - | ||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
262,488 | - | ||||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
249,406 | |||||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
772,156 | |||||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
558,642 | |||||||
Loan
payable to a non-related party, interest free, due by December 31,
2009
|
225,332 | 234,736 | ||||||
Loan
payable to a non-related party, interest free, due by May 1,
2009
|
22,007 | |||||||
Loan
payable to Jilin Bank, interest at 6.9% annually, due by January 22,
2010
|
733,500 | |||||||
Various
loans, interest free, unsecured and due on demand
|
130,238 | 130,238 | ||||||
Total
|
$ | 1,439,578 | $ | 1,967,185 |
15
NOTE
15 - LONG-TERM LOAN PAYABLE
The
Company had long term loans payable amounting to $1,320,300 as of September 30,
2009 and $1,320,390 as of December 31, 2008. The loans are secured by personal
properties of a significant shareholder of the Company. The loans payable at
September 30, 2009 comprised of the following:
The
following is the future payment schedule of the long term loan:
September 30,
2009
|
December 31,
2008
|
|||||||
Loan Payable to Runfeng Agriculture Credit Union,
interest at 8.748% and 11.02% annually respectively, due by January 26,
2011
|
$ | 1,320,300 | $ | 1,320,390 |
The
following is the future payment schedule of the long term loan
Due January 26, 2011
|
$ | 1,320,300 | $ | 1,320,300 |
NOTE
16 LOANS FROM RELATED PARTIES
As of
September 30, 2009 and December 31, 2008, the loans from related parties were
comprised of the following:
September 30, 2009
|
December 31, 2008
|
|||||||
Loans
payable to officers, interest free, due on demand, and
unsecured
|
$ | 184,662 | $ | 184,662 | ||||
Total
|
$ | 184,662 | $ | 184,662 |
Interest
expense was $0 and $6,321 for the nine month periods ended September 30, 2009
and 2008.
NOTE
17 - SHAREHOLDERS' EQUITY
The
Series A Convertible Preferred Stock is convertible over a 3 year period, into
up to 30 million shares of common stock. In particular, the holder of any shares
of Series A Convertible Preferred Stock shall have the right, at its option, (i)
at any time hereafter (except that upon any liquidation of the Company, the
right of conversion shall terminate at the close of business on the business day
fixed for payment of the amount distributable on the Series A Convertible
Preferred Stock) to convert, any such shares of Series A Convertible Preferred
Stock into such number of fully paid and nonassessable shares of Common Stock on
a six (6) for one (1) basis. No more than 1,666,666 shares of the Series A
Convertible Preferred Stock may be converted in each of the three periods
following issuance. The conversion formula is conditioned on the Company earning
no less than $3 million of net income in for the fiscal year ending December 31,
2007; $4 million of net income in the fiscal year ending December 31, 2008 and
$5 million of net income in the fiscal year ending December 31, 2009. In the
event that in any of the three fiscal years, the Company earns less than
required net income amounts for conversion, then the conversion right shall be
proportionately reduced by the amount of the shortfall below the required net
income amount, with the "catch-up" right to convert additional shares to the
extent that the net income exceeds $3 million; $4 million and $5 million
respectively in each of the three consecutive years. In no event shall this
conversion right allow for the conversion of the Series A Preferred Stock into
more than 6 common shares for each share of Series A Preferred Stock over the
course of the aforementioned three calendar years. The net income requirements
shall be based upon an audit of the revenues for each fiscal year. All
conversions shall be made within 30 days of the completion of such
audit.
As of
September 30, 2009 and December 31, 2008, the Company had 32,110,540 and
31,400,540 shares of common stock issued and outstanding,
respectively.
During
the nine month period ended September 30, 2009, the Company issued 10,000 shares
for website designing services and 100,000 shares for legal services. The shares
were valued at the fair market value of $9,900 and expensed during the nine
month period ended September 30, 2009 in the accompanying consolidated financial
statements.
16
During
the nine month period ended September 30, 2009 the Company entered into a
consulting agreement with an investor relation firm to provide investor relation
and public relation services. The agreement is for a period of 1 year and the
Company agreed to issue 300,000 shares of restricted common stock and 300,000
warrants at exercise prices ranging from $1 per share to $2 per share, to the
investor relation firm. The Company valued the shares at the fair market value
of $30,000 and expensed $17,500 during the nine month period ended September 30,
2009 in the consolidated financial statements.
During
the nine month period ended September 30, 2009 the Company entered into a
consulting agreement with an investor relation firm to provide investor relation
and public relation services. The agreement is for a period of 1 year and the
Company agreed to issue 600,000 shares of restricted common stock to the
investor relation firm. The Company valued the shares at the fair market value
of $72,000 and expensed $48,000 during the nine month period ended September 30,
2009 in the consolidated financial statements. As of September 30, 2009, 300,000
of such shares are still not issued and are included in the shares to be issued.
The unamortized part of the fee has been netted out of the amount of shares to
be issued.
On April
1, 2008, the Company issued to Investor Relations International (“IRI”) 250,000
restricted common stocks valued at $275,000, to render investor relations and
financial communication services. The Company amortized the prepaid consulting
over 1 year period based upon the terms of the agreement.
As of
October 30, 2008, the Company sold 108,695 shares to an unrelated party for
$50,000. The amount was received directly by a related party, and the
Company shows a receivable from the related party for such
amount. The related party receivable is interest free, due on demand,
unsecured and has been reflected in the equity section in the accompanying
consolidated financial statements.
NOTE
18 – WARRANTS
Following
is a summary of the warrant activity for the period ended September 30,
2009:
Outstanding,
December 31, 2008
|
2,022,080 | |||
Granted
during the year
|
300,000- | |||
Expired
during the year
|
( 472,080 | ) | ||
Exercised during the year
|
- | |||
Outstanding, September 30,
2009
|
1,850,000 |
Following
is a summary of the status of warrants outstanding at September 30,
2009:
Outstanding Warrants
|
Exercisable Warrants
|
|||||||||||||||||||
Exercise
Price
|
Number of
Warrants
|
Average Remaining
Contractual Life
|
Average Exercise
Price
|
Number of
Warrants
|
Intrinsic
Value
|
|||||||||||||||
$0.5 - $4
|
1,850,000 | 3.37 | $ | 1.01 | 1,850,000 | 362,500 |
The
assumptions used in calculating the fair value of options granted using the
Black-Scholes option-pricing model are as follows:
The
300,000 warrants granted during the nine month period ended September
30, 2009:
Risk-free
interest rate
|
2.63 | % | ||
Expected
life of the warrants
|
5
years
|
|||
Expected
volatility
|
217 | % | ||
Expected
dividend yield
|
0 |
During
the nine month period ended September 30, 2009 the Company granted
300,000 warrants at exercise prices ranging from $1 per share to $2 per share,
to an investor relation firm. The Black-Scholes fair market value of the
warrants was $51,943. The Company recorded an expense of $30,300 during the nine
month period ended September 30, 2009 in the consolidated financial statements
for the warrants.
17
NOTE
19 – COMMITMENTS
Consulting
agreements
On April
1, 2008, the Company signed a letter of engagement with Investor Relations
International (“IRI”). According to the terms of the agreement, IRI
agreed to perform investor relations and financial communication services. The
agreement was for a twelve-month period and the Company agreed to pay $10,000
per month to IRI, issue 250,000 shares of restricted common stock, and issue
300,000 warrants at an exercise price from $1.50 to $4.00 per
share. During the nine month period ended September 30, 2009, the
Company expensed $141,566 in the consolidated financial statements.
During
the nine month period ended September 30, 2009 the Company entered into a
consulting agreement with an investor relation firm to provide investor relation
and public relation services. The agreement is for a period of 1 year and the
Company agreed to issue 600,000 shares of restricted common stock to the
investor relation firm. The Company recorded an expense of $ 48,000 during the
nine month period ended September 30, 2009 in the consolidated financial
statements. As of September 30, 2009, 300,000 of such shares are still not
issued and are included in the shares to be issued. The unamortized part of the
fee has been netted out of the amount of shares to be issued.
On
September 25, 2009, the board of the Company approved a private placement of
their equity securities. The Company will issue a total of 3,338,385
shares of our common stock, restricted in accordance with Rule 144, to 157
accredited investors, for total consideration of $467,369. In
addition, the Company will issue to the investors warrants to acquire another
3,338,385 shares of our common stock at $0.35 per share, exercisable for a
period of three years. The issuances were exempt from registration
pursuant to Rule 506 of Regulation D promulgated under the Securities Act of
1933, and all of the investors were accredited. As of September 30, 2009, the
shares have not been issued.
Leases
The
Company leases its operating locations. Initial terms are typically 5
to 10 years, followed by additional terms containing priority of renewal options
at the maturity of the lease agreements, and may include rent escalation
clauses. The company recognizes rent expense on a straight-line basis
over the term of the lease.
Minimum
rental commitments at September 30, 2009, under all leases having an initial or
remaining non-cancelable term of more than one year are shown:
2010
|
$ | 1,017,753 | ||
2011
|
911,218 | |||
2012
|
268,933 | |||
2013
|
60,753 | |||
2014
|
- | |||
Total minimum lease
payments
|
$ | 2,258,657 |
The
company sub-leases its building to an unrelated company. The lease
term is one year. The company recognizes rent income on a
straight-line basis over the term of the lease.
Legal
proceedings:
On or
about October 17, 2008, a former officer initiated an action in the Superior
Court for the State of California, County of Los Angeles, Central District,
against the Company alleging claims for damages related to an alleged employment
agreement. On December 29, 2008, the Company filed an Answer to the
Complaint. The Company strongly disputes the claims and is diligently
defending against them. The matter went to trial on or about November 2, 2009
and concluded as of November 9, 2009. The case resulted in a judgment
against the Company for $641,018. The Company has accrued $641,018 in the
accompanying financial statements.
18
The
Company was defending itself against claims for open account and intentional
misrepresentation. The Plaintiff sought past due attorneys’ fees for
services rendered in the amount of $193,100. The Plaintiff also
sought 67,000 shares of the Company’s common stock. The Plaintiff filed a motion
to enforce the Company’s settlement to receive up to $50,000 judgment and
200,000 to 400,000 shares of the Company’s common stock. At the
hearing to enforce the settlement, the court entered judgment against the
Company for $50,000 plus 200,000 shares of the Company’s common
stock. The court ordered the Company to issue an additional 200,000
shares of the Company’s common stock as collateral for the
$50,000. So far, the $50,000 has not been paid the shares have not
been issued. The Company has accrued an aggregate sum of $127,397 for the cash
to be paid and for the fair market value of the shares to be
issued.
The
Company was also involved in a legal proceeding filed in Orange County Superior
Court on or about November 9, 2004. In this action, the
Cross-Complainant, Terry Koosed, sought to amend a $219,000 judgment he obtained
to include a subsidiary of the predecessor-in-interest of the Company, which was
not named or a participant in such lawsuit. On or about May 8, 2009, the Orange
County Superior Court rendered a decision to enter a judgment of $219,000
against the Company. The Company has accrued $219,000 in the accompanying
financial statements.
NOTE
20 – SEGMENT INFORMATION
The
Company operates in three business segments: retail drug stores, pharmaceutical
medicine wholesales and ginseng product sales. These segments were identified
based on their separate and distinct products and services, technology,
marketing strategies and management reporting. Management evaluates the
segments’ operating performance separately and allocates resources based on
their respective financial condition, results of operations and cash flows.
Inter-segment transactions and balances are eliminated in
consolidation.
The
retail drug store segment is complemented by such core front-end categories as
over-the-counter medications, health and beauty products, and other
items. As of September 30, 2009, the retail drug store segment
operated 73 retail stores with business area of 9,311 square meters in
three cities in China.
The
pharmaceutical medicine wholesales segment, operated through Yongxin, provides
logistics wholesale distribution of over-the-counter and prescribed medicines to
hospitals, clinics, medical institutions and retail drug stores.
The
ginseng products segment operated through Dingjian provides processing and
manufacturing ginseng electuary, pellets and liquid extracts that are
distributed by wholesalers and sold in retail drug stores.
The
following table summarizes significant financial information by
segment:
9-30-2009
|
9-30-2008
|
|||||||
Revenues
from unaffiliated customers
|
||||||||
Retail
drug stores
|
$ | 10,295,688 | $ | 8,795,741 | ||||
Pharmaceutical
medicine wholesales
|
22,603,169 | 39,800,502 | ||||||
Unallocated
|
1,000 | |||||||
Revenues
from inter-company sales
|
(3,699,532 | ) | (3,572,046 | ) | ||||
Consolidated
Totals
|
$ | 29,199,325 | $ | 45,025,197 | ||||
Net
income:
|
||||||||
Retail
drug stores
|
$ | 1,185,445 | $ | 791,482 | ||||
Pharmacy
wholesales
|
2,069,823 | 3,709,393 | ||||||
Unallocated
|
(344,024 | ) | (402,321 | ) | ||||
Net
income from inter-company
|
(303,591 | ) | (71,441 | ) | ||||
Consolidated
Totals
|
$ | 2,607,653 | $ | 4,027,113 | ||||
Depreciation
and amortization:
|
||||||||
Retail
drug stores
|
$ | 109,037 | $ | 139,916 | ||||
Pharmacy
wholesales
|
95,700 | 86,595 | ||||||
Unallocated
|
||||||||
Consolidated
Totals
|
$ | 204,737 | $ | 228,046 | ||||
Capital
expenditures:
|
||||||||
Retail
drug stores
|
$ | 135,520 | $ | 789,133 | ||||
Pharmacy
wholesales
|
942,491 | 3,662,581 | ||||||
Consolidated
Totals
|
$ | 1,078,011 | $ | 4,451,714 | ||||
Identifiable
assets:
|
||||||||
Retail
drug stores
|
$ | 9,058,930 | $ | 8,580,006 | ||||
Pharmacy
wholesales
|
29,850,960 | 22,461,560 | ||||||
Unallocated
|
8,258 | |||||||
Consolidated
Totals
|
$ | 38,909,890 | $ | 31,049,824 |
19
NOTE
21 – STATUTORY RESERVE
As
stipulated by the Company Law of the People’s Republic of China (PRC), net
income after taxation can only be distributed as dividends after appropriation
has been made for the following:
|
i.
|
Making
up cumulative prior years’ losses, if
any;
|
|
ii.
|
Allocations
to the “Statutory Surplus Reserve” of at least 10% of income after tax, as
determined under PRC accounting rules and regulations, until the fund
amounts to 50% of the Company’s registered
capital;
|
|
iii.
|
Allocations
of 5% to 10% of income after tax, as determined under PRC accounting rules
and regulations, to the Company’s “Statutory Common Welfare Fund”, which
is established for the purpose of providing employee facilities and other
collective benefits to the Company’s employees; and statutory common
welfare fund is no longer required per the new cooperation law executed in
2006.
|
|
iv.
|
Allocations
to the discretionary surplus reserve, if approved in the stockholders’
general meeting.
|
In
accordance with the Chinese Company Law, the Company allocated 10% of its annual
net income, amounting to $329,564 and $443,207 as statutory reserve for the nine
month periods ended September 30, 2009 and 2008.
NOTE
22 - DISCONTINUED OPERATIONS
On
September 30, 2005, Software Education of America, Inc., subsidiary of
Nutradyne, filed a petition in bankruptcy under Chapter 7 of the U.S. Bankruptcy
Code. The petition was necessitated because SEA was unable to continue to meet
its financial obligations. SEA is presented in the accompanying financial
statements as a discontinued operation.
Balance
Sheet information for the discontinued subsidiaries of Nutradyne, SEA and Global
as of September 30, 2009 is as follows:
Assets:
|
||||
Cash
|
$ | 46 | ||
Liabilities:
|
||||
Accounts
payable
|
$ | 227,636 | ||
Accrued
expenses
|
238,581 | |||
Notes
payable
|
162,666 | |||
Total
liabilities
|
$ | 628,883 | ||
Net
liabilities of discontinued operations
|
$ | 628,837 |
Notes
payable consist of two unsecured, non-interest bearing notes payable to two
former stockholders of SEA totaling $16,666 due January 15, 2005. No payments
have been made.
Notes
payable also include a $146,000 line of credit acquired from SEA and converted
into a term loan payable with interest at the prime rate plus 3.5% secured by
all assets of SEA of approximately $83,000 and guaranteed by the former
stockholders of SEA. This loan is payable in monthly principal payments of
$6,083 plus interest until November 15, 2006, at which time all unpaid principal
and accrued interest is due. A technical event of default occurred with
this note.
20
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of
Operations
The
following discussion relates to a discussion of the financial condition and
results of operations of China Yongxin Pharmaceuticals Inc. (formerly Digital
Learning Management Corporation and Nutradyne Group, Inc.) (the “Company") and
its subsidiaries. This management's discussion and analysis of
financial condition and results of operations for the three month and nine month
periods ending September 30, 2009 and September 30, 2008 should be read in
conjunction with its financial statements and the related notes, and the other
financial information included in this report.
Forward-Looking
Statements
The
following discussion should be read in conjunction with our condensed
consolidated financial statements and related notes included elsewhere in this
report. This report contains forward-looking statements. The words
"anticipated," "believe," "expect, "plan," "intend," "seek," "estimate,"
"project," "could," "may" and similar expressions are intended to identify
forward-looking statements. These statements include, among others, information
regarding future operations, future capital expenditures, and future net cash
flow. Such statements reflect our management's current views with
respect to future events and financial performance and involve risks and
uncertainties, including, without limitation, general economic and business
conditions, changes in foreign, political, social, and economic conditions,
regulatory initiatives and compliance with governmental regulations, the ability
to achieve further market penetration and additional customers, and various
other matters, many of which are beyond our control. Should one or
more of these risks or uncertainties occur, or should underlying assumptions
prove to be incorrect, actual results may vary materially and adversely from
those anticipated, believed, estimated or otherwise
indicated. Consequently, all of the forward-looking statements made
in this report are qualified by these cautionary statements and there can be no
assurance of the actual results or developments.
Overview
The
Company was incorporated in Delaware on February 18, 1999 under the name of
FreePCSQuote. The Company through its Chinese subsidiaries is engaged in the
wholesale distribution of pharmaceuticals and medical-related products, and the
sale and distribution of pharmaceuticals, health and beauty products, ginseng
and herbal supplements, and other healthcare products through retail operations
in the PRC.
On
December 21, 2006, Changchun Yongxin Dirui Medical Co., Ltd. (“Yongxin”), a
company organized in the People’s Republic of China (“China”) and all of the
shareholders of Yongxin entered into a share exchange agreement (“Share Exchange
Agreement”) with the Company. The Share Exchange Agreement was amended on June
15, 2007 (the “Amended Exchange Agreement”). On November 16, 2007,
Yongxin and the Company closed on the share exchange under the Amended Exchange
Agreement. However, it was improperly documented in the Share
Exchange Agreement, that the Yongxin shareholders and the Company agreed that
the Yongxin shareholders sold and the Company acquired 100% of the equity
interests of Yongxin. On April 12, 2008, we entered into a second amendment to
the Share Exchange Agreement (“Second Amended Exchange Agreement”) with Yongxin,
effective November 16, 2007, to reflect that the Company in fact desired to
acquire from the Yongxin shareholders, and Yongxin shareholders desired to sell
to the Company, only 80% of the equity interest of Yongxin in exchange for the
issuance by the Company of an aggregate of 21,000,000 shares of the Company's
common stock and 5,000,000 shares of the Company's Series A Preferred Stock to
the Yongxin shareholders and/or their designees.
The
Series A Convertible Preferred Stock is convertible over a 3-year period, into
up to 30 million shares of common stock. In particular, the holder of any shares
of Series A Convertible Preferred Stock shall have the right, at its option, (i)
at any time hereafter (except that upon any liquidation of the Company, the
right of conversion shall terminate at the close of business on the business day
fixed for payment of the amount distributable on the Series A Convertible
Preferred Stock) to convert, any such shares of Series A Convertible Preferred
Stock into such number of fully paid and nonassessable shares of Common Stock on
a six (6) for one (1) basis. No more than 1,666,666 shares of the Series A
Convertible Preferred Stock may be converted in each of the three periods
following issuance as detailed below. The conversion formula is conditioned on
the Company earning no less than $3 million of net income in for the fiscal year
ending December 31, 2007, $4 million of net income in the fiscal year ending
December 31, 2008, and $5 million of net income in the fiscal year ending
December 31, 2009. In the event that in any of the three fiscal years, the
Company earns less than required net income amounts for conversion, then the
conversion right shall be proportionately reduced by the amount of the shortfall
below the required net income amount, with the "catch-up" right to convert
additional shares to the extent that the net income exceeds $3 million, $4
million and $5 million, respectively, in each of the three consecutive years. In
no event shall this conversion right allow for the conversion of the Series A
Preferred Stock into more than 6 common shares for each share of Series A
Preferred Stock over the course of the aforementioned three fiscal years. The
net income requirements shall be based upon an audit of the revenues for each
fiscal year. All conversions shall be made within 30 days of the completion of
such audit.
21
For
accounting purposes, the share exchange transaction has been accounted for as a
reverse merger, since the stockholders of Yongxin own a majority of the issued
and outstanding shares of common stock of the Company, and the directors and
executive officers of Yongxin became the directors and executive officers of the
Company. This acquisition was accounted for at historical cost in a
manner similar to that in pooling of interests method since after the
acquisition, the former shareholders of Yongxin acquired majority of the
outstanding shares of the Company. The financial statements of the legal
acquirer are not significant; therefore, no pro forma financial information is
submitted. The historical financial statements are those of "Changchun Yongxin
Dirui Medical Co, Inc. & Subsidiaries."
Yongxin
was established in 1993. The Company’s operations are based in Changchun City,
Jilin Province, China.
In
2004, Yongxin established Jilin Province Yongxin Chain Durgstore Ltd. (“Yongxin
Drugstore”) with an investment of RMB 2,500,000 (equivalent to $303,000) to
develop customer-terminal network market. In July 2005, the Company obtained the
franchise rights in Jilin Province from American Medicine Shoppe (Meixin
International Medical Chains) and by now has developed 4 chains of “Meixin
Yongxin.” As of September 30, 2009, Yongxin Drugstore has developed a
chain of 20 retail drug stores under the “Yongxin Drugstore” name which
collectively cover 4,376 M2 of
retail space throughout Changchun, the capital of Jilin Province in northeastern
China. These drugstores sell over-the counter western and traditional Chinese
medicines and other medical-related products.
On
March 16, 2007, Yongxin Drugstore entered into various agreements with retail
drug stores in Tianjin, China, and established Tianjin Jingyongxin Chain
Drugstore Ltd. (“Jingyongxin Drugstore”) with an investment of $116,868, in
which the Company has 90% ownership. As of September 30, 2009,
Jinyongxin Drugstore has developed a 22-store retail chain with total retail
space of 2,500 M2.
On
May 15, 2007, Yongxin established Jilin Dingjian Natural & Health Products
Co., Ltd. (“Dingjian”) with an investment of $116,868 whereby the shareholders
of the company have 90% ownership of Dingjian. Dingjian was formed under
laws of the People's Republic of China and is located in Changchun City, Jilin
Province.
On
June 15 2007, Yongxin Drugstore established Baishan Caoantang Chain Drugstore
Ltd. (“Caoantang Drugstore”) with an investment of $328,430, including $144,509
in cash and $183,921in property and equipment, with an additional $80,076
payment for goodwill to be evenly paid by Yongxin over 30 months. Caoantang
Drugstore is a wholly-owned subsidiary of Yongxin Drugstore. As of September 30,
2009, Caoantang Drugstore operates a chain of 31 retail drugstores that
collectively cover 2,435 M2 of
retail space and
selling over-the counter western and traditional Chinese medicines
and other medical-related products.
On
May 5, 2008 the Company changed its name from Nutradyne Group, Inc to China
Yongxin Pharmaceuticals Inc.
2009
Overview
The
current general economic recession may affect our operations since many of our
products are discretionary and we depend to a significant extent upon a number
of factors relating to discretionary consumer spending in China. During times of
economic downturn, consumers tend to spend less on many of our products,
including cosmetics, organic products and health and nutritional
supplements.
22
Previously,
management believed that the government will pass certain favorable medical
policies (“National Medical Policy”) in the second half of 2009 which will
extend medical insurance coverage to people who live in the rural area or
countryside of China, which covers approximately 40% of the Chinese population.
Management believes the passage of the National Medical Policy will highly
benefit our sales and operations. However, the National Medical
Policy has not been passed so far and its direction is unclear. Due
to the uncertainty of the direction of the National Medical Policy, the Company
decided to make certain changes to the operation of its business in the second
half of 2009 which included shifting its focus from the wholesale sector to the
retail sector of its business. The Company will readjust its
operations and sales strategy accordingly once the direction of the National
Medical Policy becomes clear.
Since
last year, the Company has added products with higher profit margins to our
operations to increase our gross profit, such products including cosmetics and
certain health and organic products. Management believes that the
addition of such products will increase our overall gross profit in 2009 and the
next few years. Management believes that our sales and gross profit
margins will improve with better economic conditions in 2010.
Critical
Accounting Policies and Estimates
Our
management’s discussion and analysis of our financial condition and results of
operations are based on our financial statements that have been prepared in
accordance with accounting principles generally accepted in the United
States. The preparation of these financial statements requires us to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date
of the financial statements as well as the reported net sales and expenses
during the reporting periods. On an ongoing basis, we evaluate our
estimates and assumptions. We base our estimates on historical
experience and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under
different assumptions or conditions.
While our
significant accounting policies are described in note 2 to our financial
statements under the section above titled “Summary of Significant Accounting
Policies,” we believe that the following accounting policies are the most
critical to aid you in fully understanding and evaluating this management
discussion and analysis:
Basis
of Presentation
The
accompanying financial statements have been prepared in conformity with
accounting principles generally accepted in the United States of America. The
functional currency of our operating subsidiary, Changchun Yongxin Dirui Medical
Co., Ltd is Chinese Yuan Renminbi.
Translation
Adjustment
As of
September 30, 2009, the accounts of Yongxin were maintained, and its financial
statements were expressed, in Chinese Yuan Renminbi (“CNY”). Such financial
statements were translated into U.S. Dollars (“USD”) in accordance with
Statement of Financial Accounts Standards (“SFAS”) No. 52 (ASC 830), “Foreign
Currency Translation,” with the CNY as the functional currency. According to the
Statement, all assets and liabilities were translated at the current exchange
rate, stockholders’ equity are translated at the historical rates and income
statement items are translated at the average exchange rate for the period. The
resulting translation adjustments are reported under other comprehensive income
in accordance with SFAS No. 130 (ASC 220), “Reporting Comprehensive Income” as a
component of shareholders’ equity.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted
accounting principles in the United States (“GAAP”) requires management to make
certain estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates. Significant estimates include collectability of accounts
receivable, accounts payable, sales returns and recoverability of long-term
assets.
23
Principles
of Consolidation
The
consolidated financial statements include the accounts of China Yongxin
Pharmaceuticals Inc. and its subsidiaries collectively referred to within as the
“Company”. All material inter-company accounts, transactions and
profits have been eliminated in consolidation.
Non-controlling
interest
The
Company owns 90% ownership interest in Jingyongxin Drugstore and Dingjian. The
remaining 10% interest in each of the entities is owned by third parties. As at
September 30, 2009, minority interest in Jingyongxin Drugstore and Dingjian
amounted to $32,249 compared to $20,286 as at December 31, 2008. The Company
acquired 80% of Yongxin. The remaining 20% represents minority
interest amounting to $4,737,931 as at September 30, 2009 compared to $4,078,654
as at December 31, 2008.
Inventories
Inventories
are valued on a lower of weighted average cost or market
basis. Inventory includes product cost, inbound freight,
warehousing costs and vendor allowances not included as a reduction of
advertising expense. The management compares the cost of inventories with the
market value and allowance is made for writing down their inventories to market
value, if lower. Work in process inventories include the cost of raw materials
and outsource processing fees.
Property
and Equipment
Property
and equipment are recorded at cost. Depreciation is computed using the
straight-line method over useful lives ranging from 5 to 10 years. Expenditures
for maintenance and repairs are charged to earnings as incurred; additions,
renewals and betterments are capitalized. When property and equipment are
retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in
operations. Assets held under capital leases are recorded at the lesser of the
present value of the future minimum lease payments or the fair value of the
leased property. Expenditures for maintenance and repairs are charged to
operations as incurred. Depreciation of property and equipment is provided using
the straight-line method for substantially all assets with estimated lives
of:
Buildings
|
20
years
|
|
Infrastructures
and leasehold improvements
|
10
years
|
|
Equipment
(including electronic facilities, sports, education and recreation
facilities)
|
10
years
|
|
Automobiles
|
10
years
|
|
Furniture
and fixtures
|
5
years
|
|
Computer
hardware and software
|
5
years
|
Impairment
of Long-Lived Assets
Effective
January 1, 2002, the Company adopted Statement of Financial Accounting Standards
No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS
144”) (ASC 360), which addresses financial accounting and reporting for the
impairment or disposal of long-lived assets and supersedes SFAS No. 121,
“Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
be Disposed Of,” and the accounting and reporting provisions of APB Opinion No.
30, “Reporting the Results of Operations for a Disposal of a Segment of a
Business.” The Company periodically evaluates the carrying value of long-lived
assets to be held and used in accordance with SFAS 144 (ASC 360). SFAS 144 (ASC
360) requires impairment losses to be recorded on long-lived assets used in
operations when indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets are less than the assets’
carrying amounts. In that event, a loss is recognized based on the amount by
which the carrying amount exceeds the fair market value of the long-lived
assets. Loss on long-lived assets to be disposed of is determined in a similar
manner, except that fair market values are reduced for the cost of
disposal.
24
Revenue
Recognition
The
Company’s revenue recognition policies are in compliance with Staff Accounting
Bulletin (“SAB”) 104 (ASC 605). Sales revenue is recognized at the date of
shipment to customers when a formal arrangement exists, the price is fixed or
determinable, the delivery is completed, no other significant obligations of the
Company exist and collectability is reasonably assured. The Company recognizes
revenue net of an allowance for estimated returns, at the time the merchandise
is sold or services performed. The allowance for sales returns is estimated
based on the Company’s historical experience. Sales taxes are presented on a net
basis (excluded from revenues and costs). Payments received before all of the
relevant criteria for revenue recognition are satisfied are recorded as unearned
revenue.
Fair
Value of Financial Instruments
Statement
of Financial Accounting Standard No. 107 (ASC 825), “Disclosures about Fair
Value of Financial Instruments”, requires that the Company disclose estimated
fair values of financial instruments. The carrying amounts reported in the
statements of financial position for current assets and current liabilities
qualifying as financial instruments are a reasonable estimate of fair
value.
Stock
Based Compensation
Effective
January 1, 2006, the Company adopted Statement No. 123R, Share-Based
Payment (“SFAS 123R”) (ASC 718), which requires companies to measure and
recognize compensation expense for all stock-based payments at fair value. SFAS
123R is being applied on the modified prospective basis. Prior to the adoption
of SFAS 123R, the Company accounted for its stock-based compensation plan s
under the recognition and measurement principles of Accounting Principles Board
(“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees”,
and related interpretations, and accordingly, recognized no compensation expense
related to the stock-based plans. Under the modified prospective approach, SFAS
123R applies to new awards and to awards that were outstanding on
January 1, 2006 that are subsequently modified, repurchased or
cancelled.
Recent
Accounting Pronouncements
In June
2009, the FASB issued ASC 105 (previously SFAS No. 168, The FASB Accounting
Standards Codification and the Hierarchy of Generally Accepted Accounting
Principles ("GAAP") - a replacement of FASB Statement No. 162), which will
become the source of authoritative accounting principles generally accepted in
the United States recognized by the FASB to be applied to nongovernmental
entities. The Codification is effective in the third quarter of 2009, and
accordingly, the Quarterly Report on Form 10-Q for the quarter ending
September 30, 2009 and all subsequent public filings will reference the
Codification as the sole source of authoritative literature. The Company does
not believe that this will have a material effect on its consolidated financial
statements.
In June
2009, the FASB issued ASC 855 (previously SFAS No. 165, Subsequent Events),
which establishes general standards of accounting for and disclosures of events
that occur after the balance sheet date but before the financial statements are
issued or available to be issued. It is effective for interim and annual periods
ending after June 15, 2009. There was no material impact upon the adoption of
this standard on the Company’s consolidated financial statements.
In
June 2009, the FASB issued ASC 860 (previously SFAS No. 166,
“Accounting for Transfers of Financial Assets”) , which requires additional
information regarding transfers of financial assets, including securitization
transactions, and where companies have continuing exposure to the risks related
to transferred financial assets. SFAS 166 eliminates the concept of a
“qualifying special-purpose entity,” changes the requirements for derecognizing
financial assets, and requires additional disclosures. SFAS 166 is effective for
fiscal years beginning after November 15, 2009. The Company does not
believe this pronouncement will impact its financial statements.
In
June 2009, the FASB issued ASC 810 (previously SFAS No. 167) for
determining whether to consolidate a variable interest entity. These amended
standards eliminate a mandatory quantitative approach to determine whether a
variable interest gives the entity a controlling financial interest in a
variable interest entity in favor of a qualitatively focused analysis, and
require an ongoing reassessment of whether an entity is the primary beneficiary.
These amended standards are effective for us beginning in the first quarter of
fiscal year 2010 and we are currently evaluating the impact that adoption will
have on our consolidated financial statements.
25
In August
2009, the FASB issued Accounting Standards Update (“ASU”) 2009-05, which amends
ASC Topic 820, Measuring Liabilities at Fair Value, which provides additional
guidance on the measurement of liabilities at fair value. These amended
standards clarify that in circumstances in which a quoted price in an active
market for the identical liability is not available, we are required to use the
quoted price of the identical liability when traded as an asset, quoted prices
for similar liabilities, or quoted prices for similar liabilities when traded as
assets. If these quoted prices are not available, we are required to use another
valuation technique, such as an income approach or a market approach. These
amended standards are effective for us beginning in the fourth quarter of fiscal
year 2009 and are not expected to have a significant impact on our consolidated
financial statements.
Results of
Operations
Comparison
of Three and Nine Month Periods Ended September 30, 2009 and 2008.
The
following table sets forth the results of our operations for the periods
indicated:
Three Months Ended
September
30,
|
Nine Months Ended
September
30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
|||||||||||||
Net
Revenues
|
$ | 10,844,786 | $ | 15,451,100 | $ | 29,199,325 | $ | 45,025,197 | ||||||||
Cost
of Goods Sold
|
(7,685,369 | ) | (12,412,576 | ) | (21,090,595 | ) | (36,602,807 | ) | ||||||||
Gross
profit
|
3,159,417 | 3,038,524 | 8,108,730 | 8,422,390 | ||||||||||||
Operating
Expenses:
|
||||||||||||||||
Selling
expenses
|
912,094 | 858,038 | 2,495,546 | 2,582,411 | ||||||||||||
General
and administrative
|
2,386,349 | 369,471 | 3,908,223 | 1,482,786 | ||||||||||||
Total
operating expenses
|
3,298,443 | 1,227,509 | 6,403,769 | 4,065,197 | ||||||||||||
Income
(loss) from operations
|
(139,026 | ) | 1,811,015 | 1,704,961 | 4,357,193 | |||||||||||
Other
Income (Expense):
|
||||||||||||||||
Other
income
|
1,112,309 | 683,618 | 1,906,864 | 1,517,758 | ||||||||||||
Other
expense
|
(19,981 | ) | (42,745 | ) | (40,763 | ) | (77,651 | ) | ||||||||
Interest
income (expense)
|
(6,919 | ) | (55,845 | ) | 1,066 | (282,957 | ) | |||||||||
Total
other income
|
1,085,409 | 585,028 | 1,867,166 | 1,157,150 | ||||||||||||
Operating
income before income tax & non-controlling interest
|
946,383 | 2,396,043 | 3,572,127 | 5,514,343 | ||||||||||||
Provision
for income tax
|
(233,908 | ) | (547,088 | ) | (964,474 | ) | (1,487,230 | ) | ||||||||
Net
income before non-controlling interest
|
712,475 | 1,848,955 | 2,607,653 | 4,027,113 | ||||||||||||
Non-controlling
interest
|
(240,362 | ) | (191,894 | ) | (670,747 | ) | (883,775 | ) | ||||||||
Net
income
|
472,113 | 1,657,061 | 1,936,906 | 3,143,338 | ||||||||||||
Other
Comprehensive Item
|
||||||||||||||||
Foreign
exchange translation gain
|
18,938 | 26,258 | 598 | 862,970 | ||||||||||||
Net
Comprehensive Income
|
491,051 | 1,683,319 | 1,937,504 | 4,006,308 | ||||||||||||
Earning
per share
|
||||||||||||||||
Basic
|
0.01 | 0.05 | 0.06 | 0.10 | ||||||||||||
Diluted
|
0.01 | 0.05 | 0.06 | 0.10 | ||||||||||||
Weighted
average number of shares outstanding
|
||||||||||||||||
Basic
|
31,667,062 | 31,291,845 | 31,288,904 | 31,150,819 | ||||||||||||
Diluted
|
32,125,923 | 31,291,845 | 31,747,765 | 31,150,819 |
26
Comparison
of Three Months Ended September 30, 2009 and 2008.
Net
Revenues.
For the three month period ended September 30, 2009, our net revenues decreased
approximately 29.8% from $15,451,100 for the three month period ended September
30, 2008 compared to $10,844,786 for the same period ended September 30, 2009.
Our revenues for the three months ended September 30, 2009 are lower due
to the transition of the Company’s sales strategy. Due to the
uncertainty of the direction of the National Medical Policy, as described in the
2009 overview of our business, we have reduced input into the wholesale sector
of our business and we are shifting our focus to increase the retail sector of
our business. The overall policy for our drug retail business has not
changed. The decrease of sales in our wholesale business is reflected
in the decrease of our net revenues. The Company will readjust its
operations and sales strategy accordingly once the direction of the National
Medical Policy becomes clear.
Cost of Goods
Sold. Cost of
goods sold, which consists of raw materials, direct labor, and manufacturing
overhead, was $12,412,576, or approximately 80.3% of net revenues for the three
month period ended September 30, 2008, as compared to $7,685,369, or
approximately 70.9% of net revenues for the same period in 2009. The approximate
9.4% decrease in percentage corresponded with the substantial decrease of our
sales revenues.
Gross
Profit. Our gross profit increased 4.0% from $3,038,524 for the three
month period ended September 30, 2008, as compared to $3,159,418 for the same
period ended September 30, 2009. This increase in gross profit is due
to the adjustment of our products structure with an increase of products with
higher gross profit margins. Our gross profit margin has improved
from 19.7% in 2008 to 29.1% in 2009.
Selling
Expenses.
Selling expenses, which consist of advertising and promotion expenses, freight
charges and salaries, increased approximately 6.3% from $858,038 for the three
month period ended September 30, 2008 to $912,094 or for the same period in
2009. The increase in selling expenses was mainly attributable to
cost of opening two new retail stores.
General and
Administrative Expenses. General and administrative expenses were
$369,471 for the three month period ended September 30, 2008, as compared to
$2,386,349 for the three month period ended September 30, 2009, an increase of
545.9%. This substantial increase was primarily due to the increase
of allowance for doubtful account for accounts receivable, increase in accrued
litigation fees, increase in salaries from hiring additional employees to
operate our new retail stores and an increase in auditing
expenses.
Other
Income. Other income increased 85.5% from $585,028 for the three
month period ended September 30, 2008 compared to $1,085,409 for the same period
in 2009. Our other income for the three months ended September 30,
2009 was substantial higher due to higher sponsorship and rebates received from
our customers and suppliers due to the anniversary celebration of some of our
retail stores as well as the wholesale sector of the Company.
Net
Income. Net
income decreased 71.5% from a net income of $1,657,061 for the three month
period ended September 30, 2008 to a net income of $472,113 for the three month
period ended September 30, 2009. Such decrease in net income was
mainly attributable to the increase of allowance for doubtful acount for acounts
receivable, increase in accrued litigation fees, a different collection
method utilized this year to collect sponsorships, new product entrance fees and
rebates from our customers and suppliers. In the past, we
collected sponsorships and rebates from customers and suppliers on an
annual basis at the end of third quarter. However, we started to
collect these fees on a quarterly basis starting this year, which caused a
decrease in our overall net income for the three months ended September 30,
2009.
Comparison
of Nine Months Ended September 30, 2009 and 2008.
Net
Revenues. For the nine month period ended September 30, 2009, our net
revenues decreased approximately 35.1% from $45,025,197 for the nine months
ended September 30, 2008 to $29,199,325 for the same period ended September 30,
2009. The decrease in our net revenues was attributable to a downturn
in the economy. The difficult economic conditions affected our
revenues in the first half of 2009 significantly. During times of
economic downturn, consumers tend to spend less on many of our products which
are discretionary, such as cosmetics, organic products and health and
nutritional supplements. Our revenues for the nine months ended
September 30, 2009 are also lower due to the transition of the Company’s sales
strategy. Due to the uncertainty of the direction of the National
Medical Policy, as described in the 2009 overview of our business, the Company
has reduced input into the wholesale sector of its business and is shifting its
focus to increase the retail sector of its business. The overall policy for our
drug retail business has not changed. The decrease of sales in our
wholesale business is also reflected in the decrease of our net
revenues. The Company will readjust its operations and sales strategy
accordingly once the direction of the National Medical Policy becomes
clear.
27
Cost of Goods
Sold. Cost of goods sold, which consist of raw materials, direct labor,
and manufacturing overhead, decreased from $36,602,807, or approximately 81.3%
of net revenues for the nine month period ended September 30, 2008, to
$21,090,595, or approximately 72.2% of net sales for the nine month period ended
September 30, 2009. The approximate 9.1% decrease in percentage corresponded
with the decrease of our sales revenues.
Gross
Profit. Gross profit decreased approximately 3.7% from $8,422,390 for the
nine month period ended September 30, 2008 to $8,108,729 for the nine month
period ended September 30, 2009. This decrease in gross profit
corresponded with the decrease of our sales. Management believes that
consumers are more inclined to cut down on discretionary products during an
economic recession such as cosmetics, health and organic
products. Even though our gross profit decreased slightly for the
nine months ended September 30, 2009 compared to the same period in 2008, our
gross profit margin actually improved from 18.7% for the nine months ended
September 30, 2008 compared with 27.8% for the same period in
2009. This increase in gross profit margin is due to the adjustment
of our products structure with an increase of products with higher gross profit
margins.
Selling
Expenses.
Selling expenses, which consist of advertising and promotion expenses, freight
charges and salaries, decreased approximately 3.4% from $2,582,411 for the nine
month period ended September 30, 2008 to $2,495,546 for the same period in
2009. This decrease in selling expenses was mainly due to certain
business cost-cutting efforts such as reduction of utilities usage, cutback of
office supplies and packaging of our supplies.
General and
Administrative Expenses. General and administrative expenses were
$1,482,786 for the nine month period ended September 30, 2008, as compared to
$3,908,223 for the nine month period ended September 30, 2009, an increase of
163.6%. This increase was largely due to an increase in allowance for
doubtful accounts for accounts receivable and increase in accrued litigation
fees.
Other
Income. Other income increased 25.6% from $1,157,150 for the nine
month period ended September 30, 2008 compared to $1,906,864 in the same period
in 2009. The increase in other income was mainly attributable to
higher sponsorship and rebates received from our customers and suppliers due to
the anniversary celebration of some of our retail stores as well as our
wholesale business.
Net
Income. Net
income decreased 38.4% from a net income of $3,143,338 for the nine month period
ended September 30, 2008 to a net income of $1,936,906 for the nine month period
ended September 30, 2009. Such decrease in net income was mainly
attributable to the decrease of sales due to a downturn in the economy and the
increase in allowance for doubtful accounts for accounts
receivable.
Liquidity
Cash
Flow
Net cash
flow provided by operating activities was $2,557,438 for the nine month period
ended September 30, 2009 and $3,711,860 provided by operating activities for the
nine month period ended September 30, 2008. For the nine months ended
September 30, 2009, the decrease in net cash flow provided by operating
activities was mainly due to an increase of inventory.
The
Company incurred cash outflow of $1,078,011 from investing activities during the
nine months ended September 30, 2009, as compared to cash outflow of $4,440,201
for the same period in 2008. For the nine months ended September 30, 2009,
the net cash outflow for investing activities decreased substantially because we
spent less on the remodeling and construction of our offices and retail
drugstores and the development of our ERP software.
28
Net
cash flow provided by financing activities decreased from $297,481 for the nine
months ended September 30, 2008 to a net cash flow of $752,249 used in financing
activities for the nine months ended September 30, 2009. The decrease
was mainly due to the return of a loan in the approximate amount of
$454,768.
Capital
Resources
At
September 30, 2009, we had cash and cash equivalents of $1,371,842, other
current assets of $29,216,418 and current liabilities of $17,109,915. We
presently finance our operations primarily from the cash flow from our
operations, and we anticipate that this will continue to be our primary source
of funds to finance our short-term cash needs. The Company believes that the
existing cash and cash equivalents, and cash generated from operating activities
will be sufficient to meet the needs of its current operations, including
anticipated capital expenditures and scheduled debt repayments, for the next
twelve months.
We
currently have certain material commitments for capital expenditures due to the
remodeling and construction of our offices and retail drugstores and the
development of our ERP software. The total capital expenditure budget
for 2008 was $8.1 million, of which $1.39 million is still unpaid as of
September 30, 2009. Other than working capital and loans, we
presently have no other alternative source of working capital. We may need to
raise additional working capital to complete the projects. We may seek to raise
additional capital through the sale of equity securities. No assurances can be
given that we will be successful in obtaining additional capital, or that such
capital will be available in terms acceptable to our company. At this time, we
have no commitments or plans to obtain additional capital.
Contractual Obligations and Off
Balance-Sheet Arrangements
Contractual
Obligations
This
table summarizes our known contractual obligations and commercial commitments at
September 30, 2009.
Payments Due by Period
|
||||||||||||||||||||
Total
|
Less than 1
year
|
1-3 Years
|
3-5 Years
|
5 Years +
|
||||||||||||||||
Contractual Obligations :
|
||||||||||||||||||||
Bank
Indebtedness
|
$ | 2,053,800 | $ | 733,500 | $ | 1,320,300 | $ | - | $ | - | ||||||||||
Other
Indebtedness
|
$ | 350,508 | $ | 350,508 | $ | - | $ | - | $ | - | ||||||||||
Capital
Lease Obligations
|
$ | - | $ | - | $ | - | $ | - | $ | - | ||||||||||
Operating
Leases
|
$ | 3,220,705 | $ | 1,022,801 | $ | 2,197,904 | $ | - | $ | - | ||||||||||
Purchase
Obligations
|
$ | 4,133,454 | $ | 4,133,454 | $ | - | $ | - | $ | - | ||||||||||
Total
Contractual Obligations:
|
$ | 9,758,467 | $ | 6,240,263 | $ | 3,518,204 | $ | - | $ | - |
Off-Balance
Sheet Arrangements
We
have not entered into any other financial guarantees or other commitments to
guarantee the payment obligations of any third parties. We have not entered into
any derivative contracts that are indexed to our shares and classified as
stockholder's equity or that are not reflected in our consolidated financial
statements. Furthermore, we do not have any retained or contingent interest in
assets transferred to an unconsolidated entity that serves as credit, liquidity
or market risk support to such entity. We do not have any variable interest in
any unconsolidated entity that provides financing, liquidity, market risk or
credit support to us or engages in leasing or hedging services with
us.
Item
3. Quantitative and Qualitative Discloses About Market Risk
Derivative Financial
Instruments. We do not use derivative financial instruments in our
investment portfolio and have no foreign exchange contracts. Our financial
instruments consist of cash and cash equivalents, trade accounts receivable,
accounts payable and long-term obligations. We consider investments in
highly-liquid instruments purchased with a remaining maturity of 90 days or
less at the date of purchase to be cash equivalents.
29
Interest Rates. Our exposure
to market risk for changes in interest rates relates primarily to our short-term
obligations; thus, fluctuations in interest rates would not have a material
impact on the fair value of these securities. At September 30, 2009, we had
approximately $1,371,842 in cash and cash equivalents. A hypothetical 10%
increase or decrease in interest rates would not have a material impact on our
earnings or loss, or the fair market value or cash flows of these
instruments.
Foreign Exchange Rate. We use
the United States Dollar (“U.S. Dollars”) for financial reporting purposes but
all of our sales and inputs are transacted in Renminbi (“RMB”). As a result,
changes in the relative values of U.S. Dollars and RMB affect our reported
levels of revenues and profitability as the results are translated into U.S.
Dollars for reporting purposes. However, since we conduct our sales and purchase
inputs in RMB, fluctuations in exchange rates are not expected to significantly
affect our financial stability, or gross and net profit margins. We do not
currently expect to incur significant foreign exchange gains or losses, or gains
or losses associated with any foreign operations. During the nine
months ended September 30, 2009, we recorded a net foreign currency gain of $598
compared to a net foreign currency gain of $862,970 for the same
period in 2008.
Item
4. Controls and Procedures
Evaluation of Disclosure Controls
and Procedures
Disclosure
controls and procedures are controls and other procedures that are designed to
ensure that information required to be disclosed by us in the reports that we
file or submit under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Securities and Exchange
Commission's rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information
required to be disclosed by the Company in the reports that we file or submit
under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the SEC's rules and forms and that information
required to be disclosed by us in the reports that we file or submit under the
Exchange Act is accumulated and communicated to our management, including our
principal executive and financial officers, as appropriate to allow timely
decisions regarding required disclosure.
As
of the end of the period covered by this quarterly report, we conducted an
evaluation, under the supervision and with the participation of our Chief
Executive Officer and Chief Financial Officer, of our disclosure controls and
procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange
Act). Based upon this evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that the Company's disclosure controls and
procedures are effective.
Changes
in Internal Control Over Financial Reporting
Based on
the evaluation of our management as required by paragraph (d) of Rule 13a-15 or
15d-15 of the Exchange Act, there were no changes in our internal control over
financial reporting that occurred during our last fiscal quarter that have
materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
Part II.
Other Information
Item 1. Legal
Proceedings
On or
about October 17, 2008, in a case called Craig
Nagasugi v. Digital Learning Management Corporation, et al., a former officer initiated
an action in Los Angeles Superior Court, Central District, against the Company
alleging claims for damages related to an alleged employment
agreement. On December 29, 2008, the Company filed an Answer to the
Complaint. The Company strongly disputed the claims and diligently
defended against them. The matter went to trial on or about November 2, 2009 and
concluded as of November 9, 2009. The case resulted in a judgment
against the Company for $641,018.
30
Under
Allaudin
Jinnah v. China Yongxin Pharmaceuticals, Inc., filed in Los Angeles
Superior Court, Central District, on or about June 27, 2008, the Company was
defending itself against claims for open account and intentional
misrepresentation. The Plaintiff sought past due attorneys’ fees for
services rendered in the amount of $193,100. The Plaintiff also
sought 67,000 shares of the Company’s common stock. The Plaintiff filed a motion
to enforce the Company’s settlement to receive up to $50,000 judgment and
200,000 to 400,000 shares of the Company’s common stock. At the hearing to
enforce the settlement, the court entered judgment against the Company for
$50,000 plus 200,000 shares of the Company’s common stock. The court
ordered the Company to issue an additional 200,000 shares of the Company’s
common stock as collateral for the $50,000. So far, the $50,000 has not
been paid and the shares have not been issued.
The
Company was also involved in a legal proceeding called Wells
Fargo Bank. N.A.. v. Software Education for America Inc. filed in Orange
County Superior Court on or about November 9, 2004. In this action,
the Cross-Complainant, Terry Koosed, sought to amend a $219,000 judgment he
obtained to include a subsidiary of the predecessor-in-interest of the Company,
which was not named or a participant in such lawsuit. On May 8, 2009,
the Orange County Superior Court rendered a decision to enter a judgment of
$219,000 against the Company. So far, the judgment has not been
paid.
Under Adnan
Mann v. China Yongxin Pharmaceuticals, Inc., on or about March 10, 2009, a
former employee filed claims for unpaid wages and penalties under the California
Labor Code and applicable Industrial Wage Orders. On July 10, 2009, the
Company filed an Answer to the Complaint denying liability. This matter is
presently in the discovery stage and trial has been set for May 10,
2010.
Item
1A. Risk Factors
Any
investment in our securities involves a high degree of risk. Potential investors
should carefully consider the material risks described below and all of the
information contained in this Form 10-Q before deciding whether to purchase any
of our securities. Our business, financial condition or results of operations
could be materially adversely affected by these risks if any of them actually
occur. The shares of our common stock are currently quoted on the
Over-the-Counter Bulletin Board, or OTCBB under the symbol "CYXN." If and when
our securities are traded, the trading price could decline due to any of these
risks, and an investor may lose all or part of his or her investment. Some
of these factors have affected our financial condition and operating results in
the past or are currently affecting us. This report also contains
forward-looking statements that involve risks and uncertainties. Our actual
results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks faced described
below and elsewhere in this Form 10-Q.
RISKS
RELATED TO OUR BUSINESS
PURCHASES
OF MANY OF OUR PRODUCTS ARE DISCRETIONARY, MAY BE PARTICULARLY AFFECTED BY
ADVERSE TRENDS IN THE GENERAL ECONOMY, AND CHALLENGING ECONOMIC CONDITIONS WILL
MAKE IT MORE DIFFICULT TO GENERATE REVENUE.
The
current general economic recession and crisis and any continuing unfavorable
economic conditions may affect the success of our operations since many of our
products are discretionary and we depend to a significant extent upon a number
of factors relating to discretionary consumer spending in China. These factors
include economic conditions and perceptions of such conditions by consumers,
employment rates, the level of consumers' disposable income, business
conditions, interest rates, consumer debt levels, availability of credit and
levels of taxation in regional and local markets in China where we manufacture
and sell our products. There can be no assurance that consumer spending on many
of our products, including cosmetics, organic products and health and
nutritional supplements, will not be adversely affected by changes in general
economic conditions in China and globally.
THE
SUCCESS OF OUR BUSINESS DEPENDS ON OUR ABILITY TO MARKET AND ADVERTISE OUR
PRODUCTS EFFECTIVELY.
Our
ability to establish effective marketing and advertising campaigns is key to our
success. Our advertisements promote our merchandise and our proprietary brand of
ginseng-based products, and the pricing of such products. If we are unable to
increase awareness of our company and our products, we may not be able to
attract new customers. Our marketing activities may not be successful in
promoting our products or pricing strategies. We cannot assure you that our
marketing programs will be adequate to support our future growth, which may
result in a material adverse effect on our results of
operations.
31
WE
MAY BE UNABLE TO IDENTIFY AND RESPOND EFFECTIVELY TO SHIFTING CUSTOMER
PREFERENCES, AND WE MAY FAIL TO OPTIMIZE OUR PRODUCT OFFERING AND INVENTORY
POSITION.
Consumer
preferences in the drugstore industry change rapidly and are difficult to
predict. The success of our business depends on our ability to predict
accurately and respond to future changes in consumer preferences, carry the
inventory demanded by customers, deliver the appropriate quality of products,
price products correctly and implement effective purchasing procedures. We must
optimize our product selection and inventory positions based on consumer
preferences and sales trends. If we fail to anticipate, identify or react
appropriately to changes in consumer preferences and adapt our product selection
to these changing preferences, we could experience excess inventories, higher
than normal markdowns or an inability to sell our products, which could
significantly reduce our revenue and have a material adverse effect on our
business, financial condition and results of operations.
IF
WE FAIL TO MAINTAIN OPTIMAL INVENTORY LEVELS, OUR INVENTORY HOLDING COSTS COULD
INCREASE OR CAUSE US TO LOSE SALES, EITHER OF WHICH COULD HAVE A MATERIAL
ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
While
we must maintain sufficient inventory levels to operate our business
successfully and meet our customers' demands, we must be careful to avoid
amassing excess inventory. Changing consumer demands, manufacturer backorders,
uncertainty surrounding new product launches and our increased offering of our
proprietary ginseng-based products expose us to increased inventory risks.
Demand for products can change rapidly and unexpectedly, including the time
between when the product is ordered from the supplier to the time it is offered
for sale. We carry a wide variety of products and must maintain sufficient
inventory levels of our products. We may be unable to sell certain products in
the event that consumer demand changes. Our inventory holding costs will
increase if we carry excess inventory, however, if we do not have a sufficient
inventory of a product to fulfill customer orders, we may lose orders or
customers, which may adversely affect our business, financial condition and
results of operations. We cannot assure you that we can accurately predict
consumer demand and events and avoid over-stocking or under-stocking
products.
OUR BUSINESS AND THE SUCCESS OF OUR
PRODUCTS COULD BE HARMED IF WE ARE UNABLE TO MAINTAIN OUR BRAND
IMAGE.
We
believe that establishing and strengthening our proprietary brands is critical
to achieving widespread acceptance of our products and to establishing key
strategic relationships. The importance of brand recognition will increase as
current and potential competitors enter the Chinese pharmaceutical market with
competing products. Our ability to promote and position our brands depends
largely on the success of our marketing efforts and our ability to provide high
quality products and customer service. These activities are expensive and we may
not generate a corresponding increase in sales to justify these costs. If we
fail to establish and maintain our brand, or if our brand value is damaged or
diluted, we may be unable to maintain or increase our sales or
revenue.
IF
WE ARE UNABLE TO MANAGE THE DISTRIBUTION OF OUR PRODUCTS AT OUR DISTRIBUTION
CENTERS, WE MAY BE UNABLE TO MEET CUSTOMER DEMAND.
Substantially
all of our products are distributed to our stores and our wholesale customers
through our "Logistics Center" located in our "Logistics Plaza" located in
Changchun. The efficient operation and management of this facility is essential
to our meeting customer demands ability to meet customer demand. Our business
would suffer if the operation of this facility were disrupted. Our failure to
manage this facility properly could result in higher distribution costs, excess
or sufficient inventory, or an inability to fulfill customer orders, each of
which could result in a material adverse effect on our results of
operations.
DUE
TO THE GEOGRAPHIC CONCENTRATION OF OUR SALES IN THE NORTHEAST REGION OF CHINA,
OUR RESULTS OF OPERATIONS AND FINANCIAL CONDITION ARE SUBJECT TO FLUCTUATIONS IN
REGIONAL ECONOMIC CONDITIONS.
A
significant percentage of our total sales are made in the northeast region of
China, particularly in the Jilin province. For the years ended December 31,
2008, 2007 and 2006, approximately 85%, 85% and 80% of revenues, respectively,
was generated from this area. Our concentration of sales in this area heightens
our exposure to adverse developments related to competition, as well as economic
and demographic changes in this region. Our geographic concentration might
result in a material adverse effect on our business, financial condition or
results of operations in the future.
32
WE
HAVE HISTORICALLY DEPENDED ON A LIMITED NUMBER OF CUSTOMERS FOR A SIGNIFICANT
PORTION OF OUR REVENUES AND THIS DEPENDENCE IS LIKELY TO CONTINUE.
We
have historically depended on a limited number of customers for a significant
portion of our revenues. We anticipate that a limited number of customers will
continue to contribute to a significant portion of our revenues in the future.
Maintaining the relationships with these significant customers is vital to the
expansion and success of our business, as the loss of a major customer could
expose us to risk of substantial losses. Our sales and revenue could decline and
our results of operations could be materially adversely affected if one or more
of these significant customers stops or reduces its purchasing of our products,
or if we fail to expand our customer base for our products.
CERTAIN
DISRUPTIONS IN SUPPLY OF AND CHANGES IN THE COMPETITIVE ENVIRONMENT FOR OUR
PRODUCTS MAY ADVERSELY AFFECT OUR PROFITABILITY.
We
carry a broad range of merchandise in our stores, including pharmaceuticals,
traditional Chinese medicines, herbal and nutritional supplements and cosmetics.
A significant disruption in the supply of these products could decrease
inventory levels and sales, and materially adversely affect our business.
Shortages of products or interruptions in transportation systems, labor strikes,
work stoppages, war, acts of terrorism or other interruptions to or difficulties
in the employment of labor or transportation in the markets in which we purchase
products may adversely affect our ability to maintain sufficient inventories of
our products to meet consumer demand. If we were to experience a significant or
prolonged shortage of products from any of our suppliers and could not procure
the products from other sources, we would be unable to meet customer demand,
which would adversely affect our sales, margins and customer
relations.
OUR
OPERATIONS WOULD BE MATERIALLY ADVERSELY AFFECTED IF THIRD-PARTY CARRIERS WERE
UNABLE TO TRANSPORT OUR PRODUCTS ON A TIMELY BASIS.
All
of our products are shipped through third party carriers. If a strike or other
event prevented or disrupted these carriers from transporting our products,
other carriers may be unavailable or may not have the capacity to deliver our
products to our customers and to our retail stores. If adequate third party
sources to ship our products were unavailable at any time, our business would be
materially adversely affected.
THE
MARKET FOR OUR PRODUCTS AND SERVICES IS VERY COMPETITIVE AND, IF WE CANNOT
EFFECTIVELY COMPETE, OUR BUSINESS WILL BE HARMED.
The
industries in which we operate are highly fragmented and very competitive. We
compete with local drugstores and other local manufacturers of herbal products
and with large foreign multinational companies that offer products that are
similar to ours. Some of these competitors have larger local or regional
customer bases, more locations, more brand equity, and substantially greater
financial, marketing and other resources than we have. As a result, our
competitors may be in a stronger position to respond quickly to potential
acquisitions and other market opportunities, new or emerging technologies and
changes in customer tastes. We cannot assure you that we will be able to
maintain or increase our market share against the emergence of these or other
sources of competition. Failure to maintain and enhance our competitive position
could materially adversely affect our business and prospects.
WE
MAY NOT BE SUCCESSFUL IN COMPETING WITH OTHER WHOLESALERS AND DISTRIBUTORS OF
PHARMACEUTICAL PRODUCTS IN THE TENDER PROCESSES FOR THE PURCHASE OF MEDICINES BY
STATE-OWNED AND STATE-CONTROLLED HOSPITALS.
Our
wholesale business sells various pharmaceutical products to hospitals owned and
controlled by government authorities in the PRC. Government owned hospitals
purchase pharmaceutical products by using collective tender processes. During a
collective tender process, a hospital establishes a committee of recognized
pharmaceutical experts, which assesses bids submitted by pharmaceutical
manufacturers. The hospitals may only purchase pharmaceuticals that win in
collective tender processes. The collective tender process for pharmaceuticals
with the same chemical composition must be conducted at least annually, and
pharmaceuticals that have won in the collective tender processes previously must
participate and win in the collective tender processes in the following period
before hospitals may make new purchases. If we are unable to win purchase
contracts through the collective tender processes in which we decide to
participate, we will lose market share to our competitors, and our sales and
profitability will be adversely affected.
33
COUNTERFEIT
PRODUCTS IN CHINA COULD NEGATIVELY IMPACT OUR REVENUES, BRAND REPUTATION,
BUSINESS AND RESULTS OF OPERATIONS.
Our
products are also subject to competition from counterfeit pharmaceuticals, which
are pharmaceuticals manufactured without proper licenses or approvals and are
fraudulently mislabeled with respect to their content and/or manufacturer.
Counterfeit pharmaceuticals are generally sold at lower prices than the
authentic products due to their low production costs, and in some cases are very
similar in appearance to the authentic products. Counterfeit pharmaceuticals may
or may not have the same chemical content as their authentic counterparts.
Although the PRC government has recently been increasingly active in policing
counterfeit pharmaceuticals, there is not yet an effective counterfeit
pharmaceutical regulation control and enforcement system in China. The
proliferation of counterfeit pharmaceuticals has grown in recent years and may
continue to grow in the future. Despite our implementation of quality controls,
we cannot assure you that we would not be distributing or selling counterfeit
products inadvertently. Any accidental sale or distribution of counterfeit
products can subject our company to fines, administrative penalties, litigation
and negative publicity, which could negatively impact our revenues, brand
reputation, business and results of operations.
THE
RETAIL PRICES OF SOME OF OUR PRODUCTS ARE SUBJECT TO PRICE CONTROLS BY THE PRC
GOVERNMENT, WHICH MAY AFFECT BOTH OUR REVENUES AND NET INCOME.
The
laws of the PRC permit the PRC government to fix and adjust prices of certain
pharmaceutical products, including many of those listed in the Medical Insurance
Catalog. Through these price controls, the government can fix retail prices and
set retail price ceiling for certain of the pharmaceutical products we sell.
Additionally, the PRC government may periodically adjust the retail prices of
these products downward in order to make pharmaceuticals more affordable to the
general Chinese population. While our sales of pharmaceutical products are not
affected by the price controls because we currently sell such products are
prices below the price control level, we cannot guarantee that our sales of
these products will not be affected in the future, as price controls may be
increased or may affect additional products. To the extent that we are subject
to price controls, our revenue, gross profit, gross margin and net income will
be affected because the revenue we derive from our sales will be limited and we
may face no limitation on our costs. Further, if price controls affect both our
revenue and costs, our ability to be profitable and the extent of our
profitability will be effectively subject to determination by the applicable
regulatory authorities in the PRC. Any future price controls or price reductions
may reduce our revenue and profitability and have a material adverse effect on
our financial condition and results of operations.
IF
WE DO NOT COMPLY WITH THE APPLICABLE PRC LAWS AND REGULATIONS CONTROLLING THE
SALE OF MEDICINES UNDER THE PRC NATIONAL MEDICAL INSURANCE PROGRAM, WE MAY BE
SUBJECT TO FINES AND OTHER PENALTIES.
Persons
eligible to participate in the PRC National Medical Insurance Program can buy
medicines that have been included in the medical insurance catalog using a
medical insurance card in an authorized pharmacy. The applicable PRC government
social security bureau then reimburses the pharmacy. PRC law also forbids
pharmacies from selling goods other than pre-proved medicines when purchases are
made with medical insurance cards. While we have established procedures to
prevent our drugstores from selling unauthorized goods to customers who make
purchases with medical insurance cards, we cannot assure you that these
procedures will be properly followed at all times in all of our stores.
Violations of this prohibition by any of our drugstores may result in the
revocation of its status as an authorized pharmacy. Additionally, we
could be subject to other fines or other penalties, and to negative publicity,
which could damage our company's reputation and have a material adverse effect
on our results of operations.
34
OUR
CERTIFICATES, PERMITS, AND LICENSES RELATED TO OUR OPERATIONS ARE SUBJECT TO
GOVERNMENTAL CONTROL AND RENEWAL AND FAILURE TO OBTAIN RENEWAL WILL CAUSE ALL OR
PART OF OUR OPERATIONS TO BE TERMINATED.
We
are subject to various PRC laws and regulations pertaining to our wholesale,
retail and manufacturing operations. We have attained certificates, permits, and
licenses required for the operation of a pharmaceutical distributor and retailer
and the manufacture of herbal and nutritional products in the PRC. We cannot
assure you that we will have all necessary permits, certificates and
authorizations for the operation of our business at all times. Additionally, our
certifications, permits and authorizations are subject to periodic renewal by
the relevant government authorities. We intend to apply for renewal of these
certificates, permits and authorizations prior to their expiration. During the
renewal process, we will be re-evaluated by the appropriate governmental
authorities and must comply with the then prevailing standards and regulations
which may change from time to time. In the event that we are not able to renew
the certificates, permits and licenses, all or part of our operations may be
terminated. Furthermore, if escalating compliance costs associated with
governmental standards and regulations restrict or prohibit any part of our
operations, it may adversely affect our operations and
profitability.
WE
MAY SUFFER AS A RESULT OF PRODUCT LIABILITY OR DEFECTIVE PRODUCTS.
We
may produce or sell products which inadvertently have an adverse effect on the
health of individuals despite proper testing which may expose us to potential
product liability claims. Such claims may arise despite our quality controls,
proper testing and instruction for use of our products, either due to a defect
during manufacturing or due to the individual's improper use of the product. In
addition, we may be required to participate in a recall of defective products.
Adverse side effects or manufacturing problems could also result in adverse
publicity which could harm our business.
Existing
PRC laws and regulations do not require us to maintain third party liability
insurance to cover product liability claims. However, if a product liability
claim is brought against us, it may, regardless of merit or eventual outcome,
result in damage to our reputation, breach of contract with our customers,
decreased demand for our products, costly litigation, product recalls, loss of
revenue, and the inability to commercialize some products.
WE
CANNOT GUARANTEE THE PROTECTION OF OUR INTELLECTUAL PROPERTY RIGHTS AND IF
INFRINGEMENT OF OUR INTELLECTUAL PROPERTY RIGHTS OCCURS, INCLUDING
COUNTERFEITING OF OUR PRODUCTS, OUR REPUTATION AND BUSINESS MAY BE ADVERSELY
AFFECTED.
To
protect the reputation of our products, we have sought to file or register our
intellectual property, as appropriate, in the PRC where we have our primary
business presence. As of December 31, 2008, we had registered 4
trademarks. Our products are currently sold under these trademarks in
the PRC, and we plan to expand the sale and distribution of our products to
other international markets. We plan to apply for trademark protection of these
and other marks in the United States in connection with the expansion of our
retail drugstores into California. There is no assurance that there will not be
any infringement of our brand name or other registered trademarks or
counterfeiting of our products in the future, in China, the U.S. or elsewhere.
Should any such infringement and/or counterfeiting occur, our reputation and
business may be adversely affected. We may also incur significant expenses and
substantial amounts of time and effort to enforce our trademark rights in the
future. Such diversion of our resources may adversely affect our existing
business and future expansion plans.
IF
OUR PRODUCTS ARE ALLEGED TO OR FOUND TO CONFLICT WITH PATENTS THAT HAVE BEEN OR
MAY BE GRANTED TO COMPETITORS OR OTHERS, OUR REPUTATION AND BUSINESS MAY BE
ADVERSELY AFFECTED.
The
competitive nature of the nutritional and herbal products market make the patent
position of the manufacturers of such products subject to numerous uncertainties
related to complex legal and factual issues. While we currently do not own any
patents or license patents from third parties, other parties could bring legal
actions against us claiming damages and seeking to enjoin manufacturing and
marketing of our products for allegedly conflicting with patents held by them.
Any such litigation could result in substantial cost to us and diversion of
effort by our management and technical personnel. If any such actions are
successful, in addition to any potential liability for damages, we could be
required to obtain a license in order to continue to manufacture or market the
affected products. There can be no assurance that we would prevail in any such
action or that any license required under any such patent would be made
available on acceptable terms, if at all. Failure to obtain needed patents,
licenses or proprietary information held by others may have a material adverse
effect on our business. In addition, if we were to become involved in such
litigation, it could consume a substantial portion of our time and resources.
Also, with respect to licensed technology, there can be no assurance that the
licensor of the technology will have the resources, financial or otherwise, or
desire to defend against any challenges to the rights of such licensor to its
patents.
35
WE
RELY ON TRADE SECRET PROTECTIONS THROUGH CONFIDENTIALITY AGREEMENTS WITH OUR
EMPLOYEES, CUSTOMERS AND OTHER PARTIES; THE BREACH OF SUCH AGREEMENTS COULD
ADVERSELY AFFECT OUR BUSINESS ANDS RESULTS OF OPERATIONS.
We
also rely on trade secrets, which we seek to protect, in part, through
confidentiality and non-disclosure agreements with our employees, customers and
other parties. There can be no assurance that these agreements will not be
breached, that we would have adequate remedies for any such breach or that our
trade secrets will not otherwise become known to or independently developed by
competitors. To the extent that consultants, key employees or other third
parties apply technological information independently developed by them or by
others to our proposed projects, disputes may arise as to the proprietary rights
to such information that may not be resolved in our favor. We may be involved
from time to time in litigation to determine the enforceability, scope and
validity of our proprietary rights. Any such litigation could result in
substantial cost and diversion of effort by our management and technical
personnel.
THE
FAILURE TO MANAGE GROWTH EFFECTIVELY COULD HAVE AN ADVERSE EFFECT ON OUR
EMPLOYEE EFFICIENCY, PRODUCT QUALITY, WORKING CAPITAL LEVELS, AND RESULTS OF
OPERATIONS.
Any
significant growth in the market for our products or our entry into new markets
may require and expansion of our employee base for managerial, operational,
financial, and other purposes. As of December 31, 2008, we had approximately 642
full time employees. During any growth, we may face problems related to our
operational and financial systems and controls, including quality control and
delivery and service capacities. We would also need to continue to expand, train
and manage our employee base. Continued future growth will impose significant
added responsibilities upon the members of management to identify, recruit,
maintain, integrate, and motivate new employees.
Aside
from increased difficulties in the management of human resources, we may also
encounter working capital issues, as we will need increased liquidity to finance
the purchase of raw materials and supplies, development of new products, and the
hiring of additional employees. For effective growth management, we will be
required to continue improving our operations, management, and financial systems
and control. Our failure to manage growth effectively may lead to operational
and financial inefficiencies that will have a negative effect on our
profitability. We cannot assure investors that we will be able to timely and
effectively meet that demand and maintain the quality standards required by our
existing and potential customers.
WE
ARE DEPENDENT ON CERTAIN KEY PERSONNEL AND LOSS OF THESE KEY PERSONNEL COULD
HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Our
success is, to a certain extent, attributable to the management, sales and
marketing, and operational and technical expertise of certain key personnel.
Each of the named executive officers performs key functions in the operation of
our business. The loss of a significant number of these employees could have a
material adverse effect upon our business, financial condition, and results of
operations.
WE
ARE DEPENDENT ON A TRAINED WORKFORCE AND AN INABILITY TO RETAIN OR EFFECTIVELY
RECRUIT SUCH EMPLOYEES, INCLUDING IN-STORE PHARMACISTS FOR OUR STORES, COULD
HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
We
must attract, recruit and retain a sizeable workforce of qualified and trained
staff, including in-store pharmacists, in order to operate our retail
drugstores. Applicable PRC regulations require at least one qualified pharmacist
to be stationed in each drugstore to instruct or advise customers on
prescription medications. A shortage of pharmacists in the past few years has
occurred in the past few years due to increasing demand within the drugstore
industry as well as demand from other businesses in the healthcare industry. We
face competition for personnel from other drugstore chains, supermarkets, retail
chains, and pharmaceutical companies. We cannot assure you that we will be able
to attract, hire and retain sufficient numbers of in-store pharmacists necessary
to continue to develop and grow our business.
36
Additionally,
we must recruit and retain technically competent employees to develop and
manufacture our pharmaceutical products. Our ability to implement effectively
our business strategy and expand our operations will depend upon, among other
factors, the successful recruitment and retention of additional highly skilled
and experienced pharmacists and other technical and marketing personnel. There
is significant competition for technologically qualified personnel in our
business and we may not be successful in recruiting or retaining sufficient
qualified personnel consistent with our operational needs.
OUR
QUARTERLY RESULTS MAY FLUCTUATE BECAUSE OF MANY FACTORS AND, AS A RESULT,
INVESTORS SHOULD NOT RELY ON QUARTERLY OPERATING RESULTS AS INDICATIVE OF FUTURE
RESULTS.
Fluctuations
in operating results or the failure of operating results to meet the
expectations of public market analysts and investors may negatively impact the
value of our securities. Quarterly operating results may fluctuate in the future
due to a variety of factors that could affect revenues or expenses in any
particular quarter. Fluctuations in quarterly operating results could cause the
value of our securities to decline. Investors should not rely on
quarter-to-quarter comparisons of results of operations as an indication of
future performance. As a result of the factors listed below, it is possible that
in future periods results of operations may be below the expectations of public
market analysts and investors. This could cause the market price of our
securities to decline. Factors that may affect our quarterly results
include:
·
|
vulnerability of our business to
a general economic downturn in
China;
|
·
|
fluctuation and unpredictability
of costs related to the raw materials used to manufacture our
products;
|
·
|
seasonality of our
business;
|
·
|
changes in the laws of the PRC
that affect our operations;
|
·
|
competition from our competitors;
and
|
·
|
Our ability to obtain necessary
government certifications and/or licenses to conduct our
business.
|
OUR
STRATEGY TO ACQUIRE COMPANIES MAY RESULT IN UNSUITABLE ACQUISITIONS OR FAILURE
TO SUCCESSFULLY INTEGRATE ACQUIRED COMPANIES, WHICH COULD LEAD TO REDUCED
PROFITABILITY.
We
may embark on a growth strategy through acquisitions of companies or operations
that complement existing product lines, customers or other capabilities. We may
be unsuccessful in identifying suitable acquisition candidates, or may be unable
to consummate a desired acquisition. To the extent any future acquisitions are
completed, we may be unsuccessful in integrating acquired companies or their
operations, or if integration is more difficult than anticipated, we may
experience disruptions that could have a material adverse impact on future
profitability. Some of the risks that may affect our ability to integrate, or
realize any anticipated benefits from, acquisitions include:
·
|
unexpected losses of key
employees or customer of the acquired
company;
|
·
|
difficulties integrating the
acquired company's standards, processes, procedures and
controls;
|
·
|
difficulties coordinating new
product and process
development;
|
·
|
difficulties hiring additional
management and other critical
personnel;
|
·
|
difficulties increasing the
scope, geographic diversity and complexity of our
operations;
|
·
|
difficulties consolidating
facilities, transferring processes and
know-how;
|
·
|
difficulties reducing costs of
the acquired company's
business;
|
·
|
diversion of management's
attention from our management;
and
|
·
|
adverse impacts on existing
business relationships with
customers.
|
37
RISKS
RELATED TO US DOING BUSINESS IN CHINA
SUBSTANTIALLY
ALL OF OUR ASSETS ARE LOCATED IN THE PRC AND SUBSTANTIALLY ALL OF OUR REVENUES
ARE DERIVED FROM OUR OPERATIONS IN CHINA, AND CHANGES IN THE POLITICAL AND
ECONOMIC POLICIES OF THE PRC GOVERNMENT COULD HAVE A SIGNIFICANT IMPACT UPON THE
BUSINESS WE MAY BE ABLE TO CONDUCT IN THE PRC AND ACCORDINGLY ON THE RESULTS OF
OUR OPERATIONS AND FINANCIAL CONDITION.
Our
business operations may be adversely affected by the current and future
political environment in the PRC. The Chinese government exerts substantial
influence and control over the manner in which we must conduct our business
activities. Our ability to operate in China may be adversely affected by changes
in Chinese laws and regulations, including those relating to taxation, import
and export tariffs, raw materials, environmental regulations, land use rights,
property and other matters. Under the current government leadership, the
government of the PRC has been pursuing economic reform policies that encourage
private economic activity and greater economic decentralization. There is no
assurance, however, that the government of the PRC will continue to pursue these
policies, or that it will not significantly alter these policies from time to
time without notice.
OUR
OPERATIONS ARE SUBJECT TO PRC LAWS AND REGULATIONS THAT ARE SOMETIMES VAGUE AND
UNCERTAIN. ANY CHANGES IN SUCH PRC LAWS AND REGULATIONS, OR THE INTERPRETATIONS
THEREOF, MAY HAVE A MATERIAL AND ADVERSE EFFECT ON OUR BUSINESS.
The
PRC's legal system is a civil law system based on written statutes. Unlike the
common law system prevalent in the United States, decided legal cases have
little value as precedent in China. There are substantial uncertainties
regarding the interpretation and application of PRC laws and regulations,
including but not limited to, the laws and regulations governing our business,
or the enforcement and performance of our arrangements with customers in the
event of the imposition of statutory liens, death, bankruptcy or criminal
proceedings. The Chinese government has been developing a comprehensive system
of commercial laws, and considerable progress has been made in introducing laws
and regulations dealing with economic matters such as foreign investment,
corporate organization and governance, commerce, taxation and trade. However,
because these laws and regulations are relatively new, and because of the
limited volume of published cases and judicial interpretation and their lack of
force as precedents, interpretation and enforcement of these laws and
regulations involve significant uncertainties. New laws and regulations that
affect existing and proposed future businesses may also be applied
retroactively.
Our
principal operating subsidiary, Yongxin, is considered a foreign invested
enterprise under PRC laws, and as a result is required to comply with PRC laws
and regulations, including laws and regulations specifically governing the
activities and conduct of foreign invested enterprises. We cannot predict what
effect the interpretation of existing or new PRC laws or regulations may have on
our businesses. If the relevant authorities find us in violation of PRC laws or
regulations, they would have broad discretion in dealing with such a violation,
including, without limitation:
·
|
levying
fines;
|
·
|
revoking our business license,
other licenses or
authorities;
|
·
|
requiring that we restructure our
ownership or operations; and
|
·
|
requiring that we discontinue any
portion or all of our
business.
|
THE
SCOPE OF OUR BUSINESS LICENSE IN CHINA IS LIMITED, AND WE MAY NOT EXPAND OR
CONTINUE OUR BUSINESS WITHOUT GOVERNMENT APPROVAL AND RENEWAL,
RESPECTIVELY.
Our
principal operating subsidiary, Yongxin, is a wholly foreign-owned enterprise,
commonly known as a WFOE. A WFOE can only conduct business within its approved
business scope, which ultimately appears on its business license. Our license
permits us to design, manufacture, sell and market pharmaceutical products
throughout the PRC. Any amendment to the scope of our business requires further
application and government approval. In order for us to expand our business
beyond the scope of our license, it will be required to enter into a negotiation
with the authorities for the approval to expand the scope of our business. We
cannot assure investors that Yongxin will be able to obtain the necessary
government approval for any change or expansion of its
business.
38
OUR
BUSINESS IS SUBJECT TO A VARIETY OF ENVIRONMENTAL LAWS AND REGULATIONS. OUR
FAILURE TO COMPLY WITH ENVIRONMENTAL LAWS AND REGULATIONS MAY HAVE A MATERIAL
ADVERSE EFFECT ON OUR BUSINESS AND RESULTS OF OPERATIONS.
We
are subject to various environmental laws and regulations that require us to
obtain environmental permits and are subject to registration and inspection by
the SFDA. We have a provincial license issued by the Business Administration
Bureau, Jilin Province. Although we are currently compliant with all provisions
of our registrations and licenses, we cannot assure you that at all times we
will be in compliance with environmental laws and regulations or our
environmental permits or that we will not be required to expend significant
funds to comply with, or discharge liabilities arising under, environmental
laws, regulations and permits. Additionally, we cannot guarantee you that our
licenses and registrations will be renewed. Any non-renewal of any of our
required permits and licenses could result in the termination of our business
operations.
RECENT
PRC REGULATIONS RELATING TO ACQUISITIONS OF PRC COMPANIES BY FOREIGN ENTITIES
MAY CREATE REGULATORY UNCERTAINTIES THAT COULD RESTRICT OR LIMIT OUR ABILITY TO
OPERATE, INCLUDING OUR ABILITY TO PAY DIVIDENDS.
The
PRC State Administration of Foreign Exchange, or SAFE, issued a public notice in
January 2005 concerning foreign exchange regulations on mergers and acquisitions
in China. The public notice states that if an offshore company controlled by PRC
residents intends to acquire a PRC company, such acquisition will be subject to
strict examination by the relevant foreign exchange authorities. The public
notice also states that the approval of the relevant foreign exchange
authorities is required for any sale or transfer by the PRC residents of a PRC
company's assets or equity interests to foreign entities for equity interests or
assets of the foreign entities.
In
April 2005, SAFE issued another public notice further explaining the January
notice. In accordance with the April notice, if an acquisition of a PRC company
by an offshore company controlled by PRC residents has been confirmed by a
Foreign Investment Enterprise Certificate prior to the promulgation of the
January notice, the PRC residents must each submit a registration form to the
local SAFE branch with respect to their respective ownership interests in the
offshore company, and must also file an amendment to such registration if the
offshore company experiences material events, such as changes in the share
capital, share transfer, mergers and acquisitions, spin-off transaction or use
of assets in China to guarantee offshore obligations. The April notice also
provides that failure to comply with the registration procedures set forth
therein may result in restrictions on our PRC resident shareholders and
subsidiaries. Pending the promulgation of detailed implementation rules, the
relevant government authorities are reluctant to commence processing any
registration or application for approval required under the SAFE
notices.
On
August 8, 2006, the PRC Ministry of Commerce ("MOFCOM"), joined by the
State-owned Assets Supervision and Administration Commission of the State
Council, the State Administration of Taxation, the State Administration for
Industry and Commerce, the China Securities Regulatory Commission and SAFE,
released a substantially amended version of the Provisions for Foreign Investors
to Merge with or Acquire Domestic Enterprises (the "Revised M&A
Regulations"), which took effect September 8, 2006. These new rules
significantly revised China's regulatory framework governing onshore-to-offshore
restructurings and foreign acquisitions of domestic enterprises. These new rules
signify greater PRC government attention to cross-border merger, acquisition and
other investment activities, by confirming MOFCOM as a key regulator for issues
related to mergers and acquisitions in China and requiring MOFCOM approval of a
broad range of merger, acquisition and investment transactions. Further, the new
rules establish reporting requirements for acquisition of control by foreigners
of companies in key industries, and reinforce the ability of the Chinese
government to monitor and prohibit foreign control transactions in key
industries.
These
new rules may significantly affect the means by which offshore-onshore
restructurings are undertaken in China in connection with offshore private
equity and venture capital financings, mergers and acquisitions. It is expected
that such transactional activity in China in the near future will require
significant case-by-case guidance from MOFCOM and other government authorities
as appropriate. It is anticipated that application of the new rules will be
subject to significant administrative interpretation, and we will need to
closely monitor how MOFCOM and other ministries apply the rules to ensure its
domestic and offshore activities continue to comply with PRC law. Given the
uncertainties regarding interpretation and application of the new rules, we may
need to expend significant time and resources to maintain
compliance.
It
is uncertain how our business operations or future strategy will be affected by
the interpretations and implementation of the SAFE notices and new rules. Our
business operations or future strategy could be adversely affected by the SAFE
notices and the new rules. For example, we may be subject to more stringent
review and approval process with respect to our foreign exchange
activities.
39
THE
FOREIGN CURRENCY EXCHANGE RATE BETWEEN U.S. DOLLARS AND RENMINBI COULD ADVERSELY
AFFECT OUR FINANCIAL CONDITION.
To
the extent that we need to convert U.S. Dollars into Renminbi for our
operational needs, our financial position and the price of our common stock may
be adversely affected should the Renminbi appreciate against the U.S. Dollar at
that time. Conversely, if we decide to convert our Renminbi into U.S. Dollars
for the operational needs or paying dividends on our common stock, the dollar
equivalent of our earnings from our subsidiaries in China would be reduced
should the U.S. Dollar appreciate against the Renminbi.
Until
1994, the Renminbi experienced a gradual but significant devaluation against
most major currencies, including dollars, and there was a significant
devaluation of the Renminbi on January 1, 1994 in connection with the
replacement of the dual exchange rate system with a unified managed floating
rate foreign exchange system. Since 1994, the value of the Renminbi relative to
the U.S. Dollar has remained stable and has appreciated slightly against the
U.S. Dollar. Countries, including the United States, have argued that the
Renminbi is artificially undervalued due to China's current monetary policies
and have pressured China to allow the Renminbi to float freely in world markets.
In July 2005, the PRC government changed its policy of pegging the value of the
Renminbi to the U.S. Dollar. Under the new policy, the Renminbi is permitted to
fluctuate within a narrow and managed band against a basket of designated
foreign currencies. While the international reaction to the Renminbi revaluation
has generally been positive, there remains significant international pressure on
the PRC government to adopt an even more flexible currency policy, which could
result in further and more significant appreciation of the Renminbi against the
dollar.
FAILURE
TO COMPLY WITH THE UNITED STATES FOREIGN CORRUPT PRACTICES ACT COULD SUBJECT US
TO PENALTIES AND OTHER ADVERSE CONSEQUENCES.
As
our ultimate holding company is a Delaware corporation, we are subject to the
United States Foreign Corrupt Practices Act, which generally prohibits United
States companies from engaging in bribery or other prohibited payments to
foreign officials for the purpose of obtaining or retaining business. Foreign
companies, including some that may compete with us, are not subject to these
prohibitions. Corruption, extortion, bribery, pay-offs, theft and other
fraudulent practices may occur from time-to-time in the PRC. We can make no
assurance, however, that our employees or other agents will not engage in such
conduct for which we might be held responsible. If our employees or other agents
are found to have engaged in such practices, we could suffer severe penalties
and other consequences that may have a material adverse effect on our business,
financial condition and results of operations.
IF
WE MAKE EQUITY COMPENSATION GRANTS TO PERSONS WHO ARE PRC CITIZENS, THEY MAY BE
REQUIRED TO REGISTER WITH THE STATE ADMINISTRATION OF FOREIGN EXCHANGE OF THE
PRC, OR SAFE. WE MAY ALSO FACE REGULATORY UNCERTAINTIES THAT COULD RESTRICT OUR
ABILITY TO ADOPT AN EQUITY COMPENSATION PLAN FOR OUR DIRECTORS AND EMPLOYEES AND
OTHER PARTIES UNDER PRC LAW.
On
April 6, 2007, SAFE issued the "Operating Procedures for Administration of
Domestic Individuals Participating in the Employee Stock Ownership Plan or Stock
Option Plan of An Overseas Listed Company, also know as "Circular 78." It is not
clear whether Circular 78 covers all forms of equity compensation plans or only
those which provide for the granting of stock options. For any plans which are
so covered and are adopted by a non-PRC listed company after April 6, 2007,
Circular 78 requires all participants who are PRC citizens to register with and
obtain approvals from SAFE prior to their participation in the plan. In
addition, Circular 78 also requires PRC citizens to register with SAFE and make
the necessary applications and filings if they participated in an overseas
listed company's covered equity compensation plan prior to April 6, 2007. We
intend to adopt an equity compensation plan in the future and make option grants
to our officers and directors, most of who are PRC citizens. Circular 78 may
require our officers and directors who receive option grants and are PRC
citizens to register with SAFE. We believe that the registration and approval
requirements contemplated in Circular 78 will be burdensome and time consuming.
If it is determined that any of our equity compensation plans are subject to
Circular 78, failure to comply with such provisions may subject us and
participants of our equity incentive plan who are PRC citizens to fines and
legal sanctions and prevent us from being able to grant equity compensation to
our PRC employees. In that case, our ability to compensate our employees and
directors through equity compensation would be hindered and our business
operations may be adversely affected.
40
ANY
RECURRENCE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS), AVIAN FLU, OR ANOTHER
WIDESPREAD PUBLIC HEALTH PROBLEM, IN THE PRC COULD ADVERSELY AFFECT OUR
OPERATIONS.
A
renewed outbreak of SARS, Avian Flu or another widespread public health problem
in China, where all of our manufacturing facilities are located and where the
substantial portion of our sales occur, could have a negative effect on our
operations. Our business is dependent upon its ability to continue to
manufacture products. Such an outbreak could have an impact on our operations as
a result of:
·
|
quarantines or closures of some
of our manufacturing facilities, which would severely disrupt our
operations,
|
·
|
the sickness or death of our key
officers and employees, and
|
·
|
a general slowdown in the Chinese
economy.
|
Any
of the foregoing events or other unforeseen consequences of public health
problems could adversely affect our operations.
A
DOWNTURN IN THE ECONOMY OF THE PRC MAY SLOW OUR GROWTH AND
PROFITABILITY.
The
growth of the Chinese economy has been uneven across geographic regions and
economic sectors. There can be no assurance that growth of the
Chinese economy will be steady or that any further downturn will not have a
negative effect on our business, especially if it results in either a decreased
use of our products or in pressure on us to lower our prices.
BECAUSE
OUR BUSINESS IS LOCATED IN THE PRC, WE MAY HAVE DIFFICULTY ESTABLISHING ADEQUATE
MANAGEMENT, LEGAL AND FINANCIAL CONTROLS, WHICH IT IS REQUIRED TO DO IN ORDER TO
COMPLY WITH U.S. SECURITIES LAWS.
PRC
companies have historically not adopted a Western style of management and
financial reporting concepts and practices, which includes strong corporate
governance, internal controls and, computer, financial and other control
systems. Most of our middle and top management staff are not educated and
trained in the Western system, and we may difficulty hiring new employees in the
PRC with such training. In addition, we may have difficulty in hiring and
retaining a sufficient number of qualified employees to work in the PRC. As a
result of these factors, we may experience difficulty in establishing
management, legal and financial controls, collecting financial data and
preparing financial statements, books of account and corporate records and
instituting business practices that meet Western standards. Therefore, we may,
in turn, experience difficulties in implementing and maintaining adequate
internal controls as required under Section 404 of the Sarbanes-Oxley Act of
2002. This may result in significant deficiencies or material weaknesses in our
internal controls which could impact the reliability of its financial statements
and prevent us from complying with SEC rules and regulations and the
requirements of the Sarbanes-Oxley Act of 2002. Any such deficiencies,
weaknesses or lack of compliance could have a materially adverse effect on our
business.
INVESTORS
MAY EXPERIENCE DIFFICULTIES IN EFFECTING SERVICE OF LEGAL PROCESS, ENFORCING
FOREIGN JUDGMENTS OR BRINGING ORIGINAL ACTIONS IN CHINA BASED UPON U.S. LAWS,
INCLUDING THE FEDERAL SECURITIES LAWS OR OTHER FOREIGN LAWS AGAINST US OR OUR
MANAGEMENT.
Most
of our current operations, including the manufacturing and distribution of our
products, are conducted in China. Moreover, all but one of our directors and
officers are nationals and residents of China or Hong Kong. All or substantially
all of the assets of these persons are located outside the United States and in
the PRC. As a result, it may not be possible to effect service of process within
the United States or elsewhere outside China upon these persons. In addition,
uncertainty exists as to whether the courts of China would recognize or enforce
judgments of U.S. courts obtained against us or such officers and/or directors
predicated upon the civil liability provisions of the securities laws of the
United States or any state thereof, or be competent to hear original actions
brought in China against us or such persons predicated upon the securities laws
of the United States or any state thereof.
41
RISKS
RELATED TO OUR CAPITAL STRUCTURE
IF
WE ARE FOUND TO BE IN VIOLATION OF CURRENT OR FUTURE PRC LAWS, RULES OR
REGULATIONS REGARDING THE LEGALITY OF FOREIGN INVESTMENT IN THE PRC WITH RESPECT
TO OUR OWNERSHIP STRUCTURE, WE COULD BE SUBJECT TO SEVERE
PENALTIES.
We
conduct business operations solely in the PRC through our wholly owned
subsidiary, Yongxin, and our 90% owned subsidiary, Dingjian. We are a Delaware
corporation, most of our direct and indirect subsidiaries are companies
organized under the laws of the PRC. We are considered a foreign person or
foreign invested enterprise under PRC law. As a result, we are subject to PRC
law limitations on foreign ownership of Chinese companies. There are substantial
uncertainties regarding the interpretation and application of PRC laws and
regulations, including, but not limited to, the laws and regulations governing
our pharmaceutical distribution and retail drugstore businesses.
Accordingly,
it is possible that the relevant PRC authorities could, at any time, assert that
any portion of our existing or future ownership structure and businesses violate
existing or future PRC laws, regulations or policies. It is also possible that
the new laws or regulations governing our business operations in the PRC that
have been adopted or may be adopted in the future will prohibit or restrict
foreign investment in, or other aspects of, any of our PRC subsidiaries' and our
current or proposed businesses and operations. The effectiveness of newly
enacted laws, regulations or amendments may be delayed, resulting in detrimental
reliance by foreign investors. New laws and regulations that affect existing and
proposed future businesses may also be applied retroactively.
The PRC
government has broad discretion in dealing with violations of laws and
regulations, including:
·
|
levying
fines;
|
·
|
confiscating our
income;
|
·
|
revoking business and other
licenses;
|
·
|
requiring us to discontinue any
portion or all of our
business;
|
·
|
requiring us to restructure our
ownership structure or operations;
and
|
·
|
requiring actions necessary for
compliance.
|
In
particular, licenses and permits issued or granted to us by relevant
governmental bodies may be revoked at a later time by higher regulatory bodies.
We cannot predict the effect of the interpretation of existing or new PRC laws
or regulations on our businesses. We cannot assure you that our current
ownership and operating structure would not be found in violation of any current
or future PRC laws or regulations. As a result, we may be subject to sanctions,
including fines, and could be required to restructure our operations or cease to
provide certain services. Any of these or similar actions could significantly
disrupt our business operations or restrict us from conducting a substantial
portion of our business operations, which could materially and adversely affect
our business, financial condition and results of operations.
WE
MAY BE ADVERSELY AFFECTED BY COMPLEXITY, UNCERTAINTIES AND CHANGES IN PRC
REGULATION OF PHARMACEUTICAL BUSINESSES AND DRUGSTORE COMPANIES, INCLUDING
LIMITATIONS ON OUR ABILITY TO OWN KEY ASSETS.
The
PRC government regulates the pharmaceutical and drugstore industries including
foreign ownership of, and the licensing and permit requirements pertaining to,
companies operating in these industries. These laws and regulations are
relatively new and evolving, and their interpretation and enforcement involve
significant uncertainty. As a result, in certain circumstances it may be
difficult to determine what actions or omissions may be deemed to be a violation
of applicable laws and regulations. Issues, risks and uncertainties relating to
PRC government regulation of the pharmaceutical industry include those relating
evolving licensing practices. Permits, licenses or operations at our company may
be subject to challenge, which may disrupt our business, or subject us to
sanctions, requirements to increase capital or other conditions or enforcement,
or compromise enforceability of related contractual arrangements, or have other
harmful effects on us. Although we believe we comply with current PRC
regulations, we cannot assure you that our ownership and operating structure
comply with PRC licensing, registration or other regulatory requirements, with
existing policies or with requirements or policies that may be adopted in the
future. If the PRC government determines that we do not comply with applicable
law, it could take other regulatory or enforcement actions against us that could
be harmful to our business.
42
THERE
IS CURRENTLY A LIMITED TRADING MARKET FOR OUR COMMON STOCK, AND THERE IS NO
ASSURANCE OF A MORE ESTABLISHED PUBLIC TRADING MARKET, WHICH WOULD ADVERSELY
AFFECT THE ABILITY OF OUR INVESTORS TO SELL THEIR SECURITIES IN THE PUBLIC
MARKET.
While,
our common stock is currently listed on the Over-the-Counter Bulletin Board
("OTCBB"), there is currently a very limited trading market for our common
stock. The Financial Industry Regulatory Authority has enacted changes that
limit quotations on the OTCBB to securities of issuers that are current in their
reports filed with the Securities and Exchange Commission. The effect on the
OTCBB of these rule changes and other proposed changes cannot be determined at
this time. The OTCBB is an inter-dealer, over-the-counter market that provides
significantly less liquidity than the NASDAQ Global Market (the "NASDAQ Global
Market"). Quotes for stocks included on the OTCBB are not listed in the
financial sections of newspapers as are those for the NASDAQ Global Market.
Therefore, prices for securities traded solely on the OTCBB may be difficult to
obtain and holders of common stock may be unable to resell their securities at
or near their original offering price or at any price.
Market
prices for our common stock after the Share Exchange will be influenced by a
number of factors, including:
·
|
Our ability to obtain additional
financing and, if available, the terms and conditions of the
financing;
|
·
|
Our financial position and
results of operations;
|
·
|
Concern as to, or other evidence
of, the reliability and safety of our products and services or our
competitors' products and
services;
|
·
|
Announcements of innovations or
new products or services by us or our
competitors;
|
·
|
U.S. federal and state
governmental regulatory actions and the impact of such requirements on our
business;
|
·
|
Chinese governmental regulatory
actions and the impact of such requirements on our
business;
|
·
|
The development of litigation
against us;
|
·
|
Period-to-period fluctuations in
our operating results;
|
·
|
Changes in estimates of our
performance by any securities
analysts;
|
·
|
The issuance of new equity
securities pursuant to a future offering or
acquisition;
|
·
|
Changes in interest rates and/or
foreign currency exchange
rates;
|
·
|
Competitive developments,
including announcements by competitors of new products or services or
significant contracts, acquisitions, strategic partnerships, joint
ventures or capital
commitments;
|
·
|
Investor perceptions of us;
and
|
·
|
General economic and other
national and international
conditions.
|
43
SHARES
ELIGIBLE FOR FUTURE SALE MAY ADVERSELY AFFECT THE MARKET PRICE OF OUR COMMON
STOCK, AS THE FUTURE SALE OF A SUBSTANTIAL AMOUNT OF OUTSTANDING STOCK IN THE
PUBLIC MARKETPLACE COULD REDUCE THE PRICE OF OUR COMMON STOCK.
We
may file a registration statement to register the shares issued to the Yongxin
shareholders pursuant to the Share Exchange. All of the shares included in an
effective registration statement as described above may be freely sold and
transferred except if subject to a lock up agreement.
The
shareholders who received shares of our common stock in the Share Exchange
and/or their designees may be eligible to sell all or some of our shares of
common stock by means of ordinary brokerage transactions in the open market
pursuant to Rule 144, promulgated under the Securities Act ("Rule 144"), subject
to certain limitations. In general, pursuant to Rule 144, a non-affiliate
stockholder (or stockholders whose shares are aggregated) who has satisfied a
six-month holding period, and provided that there is current public information
available, may sell all of its securities. Rule 144 also permits the sale of
securities, without any limitations, by a non-affiliate that has satisfied a
one-year holding period. Any substantial sale of common stock pursuant to any
resale prospectus or Rule 144 may have an adverse effect on the market price of
our common stock by creating an excessive supply.
FOLLOWING
THE SHARE EXCHANGE, THE FORMER PRINCIPAL SHAREHOLDERS OF YONGXIN HAVE
SIGNIFICANT INFLUENCE OVER US.
The
former shareholders of Yongxin and their designees beneficially own or control a
majority of our outstanding shares as of December 31, 2008. If these
stockholders were to act as a group, they would have a controlling influence in
determining the outcome of any corporate transaction or other matters submitted
to our stockholders for approval, including mergers, consolidations and the sale
of all or substantially all of our assets, election of directors, and other
significant corporate actions. Such shareholders may also have the power to
prevent or cause a change in control. In addition, without the consent of the
former Yongxin shareholders, we could be prevented from entering into
transactions that could be beneficial to us. The interests of the former Yongxin
shareholders may differ from the interests of our other
stockholders.
IF
WE FAIL TO MAINTAIN EFFECTIVE INTERNAL CONTROLS OVER FINANCIAL REPORTING, THE
PRICE OF OUR COMMON STOCK MAY BE ADVERSELY AFFECTED.
We
are required to establish and maintain appropriate internal controls over
financial reporting. Failure to establish those controls, or any failure of
those controls once established, could adversely impact our public disclosures
regarding our business, financial condition or results of operations. Any
failure of these controls could also prevent us from maintaining accurate
accounting records and discovering accounting errors and financial frauds. Rules
adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley Act of 2002
require annual assessment of our internal control over financial reporting, and
attestation of this assessment by our independent registered public accountants.
The SEC extended the compliance dates for non-accelerated filers, as defined by
the SEC. Accordingly, we believe that the annual assessment of our internal
controls requirement has first applied to our annual report for the 2007 fiscal
year and the attestation requirement of management's assessment by our
independent registered public accountants has first applied to our annual report
for the 2008 fiscal year. The standards that must be met for management to
assess the internal control over financial reporting as effective are new and
complex, and require significant documentation, testing and possible remediation
to meet the detailed standards. We may encounter problems or delays in
completing activities necessary to make an assessment of our internal control
over financial reporting. In addition, the attestation process by our
independent registered public accountants is new and we may encounter problems
or delays in completing the implementation of any requested improvements and
receiving an attestation of our assessment by our independent registered public
accountants. If we cannot assess our internal control over financial reporting
as effective, or our independent registered public accountants are unable to
provide an unqualified attestation report on such assessment, investor
confidence and share value may be negatively impacted.
In
addition, management's assessment of internal controls over financial reporting
may identify weaknesses and conditions that need to be addressed in our internal
controls over financial reporting or other matters that may raise concerns for
investors. Any actual or perceived weaknesses and conditions that need to be
addressed in our internal control over financial reporting, disclosure of
management's assessment of our internal controls over financial reporting, or
disclosure of our public accounting firm's attestation to or report on
management's assessment of our internal controls over financial reporting may
have an adverse impact on the price of our common stock.
44
THE
FOREIGN CURRENCY EXCHANGE RATE BETWEEN U.S. DOLLARS AND RENMINBI COULD ADVERSELY
AFFECT OUR FINANCIAL CONDITION.
To
the extent that we need to convert U.S. Dollars into Renminbi for our
operational needs, our financial position and the price of our common stock may
be adversely affected should the Renminbi appreciate against the U.S. Dollar at
that time. Conversely, if we decide to convert our Renminbi into U.S. Dollars
for our operational needs or paying dividends on our common stock, the U.S.
Dollar equivalent of our earnings from our subsidiaries in China would be
reduced should the U.S. Dollar appreciate against the Renminbi.
Until
1994, the Renminbi experienced a gradual but significant devaluation against
most major currencies, including dollars, and there was a significant
devaluation of the Renminbi on January 1, 1994 in connection with the
replacement of the dual exchange rate system with a unified managed floating
rate foreign exchange system. Since 1994, the value of the Renminbi relative to
the U.S. Dollar has remained stable and has appreciated slightly against the
U.S. Dollar. Countries, including the United States, have argued that the
Renminbi is artificially undervalued due to China's current monetary policies
and have pressured China to allow the Renminbi to float freely in world markets.
In July 2005, the PRC government changed its policy of pegging the value of the
Renminbi to the dollar. Under the new policy the Renminbi is permitted to
fluctuate within a narrow and managed band against a basket of designated
foreign currencies. While the international reaction to the Renminbi revaluation
has generally been positive, there remains significant international pressure on
the PRC government to adopt an even more flexible currency policy, which could
result in further and more significant appreciation of the Renminbi against the
dollar.
WE
MAY NOT BE ABLE TO ACHIEVE THE FULL EXTENT OF THE BENEFITS WE EXPECT FROM THE
SHARE EXCHANGE.
On
April 12, 2008, we entered into the Second Amended Exchange Agreement to the
Share Exchange Agreement with Yongxin, effective November 16, 2007, and all of
the shareholders of Yongxin, pursuant to which we agreed to acquire 80% of the
issued and outstanding equity interest of Yongxin in exchange for shares of our
common stock. On November 16, 2007, the Share Exchange closed, Yongxin became
our 80%-owned subsidiary and we assumed the business operations Yongxin. We also
have a new Board of Directors and management consisting of persons from Yongxin
and changed our corporate name from "Digital Learning Management Corporation" to
"Nutradyne Group, Inc."
We may
not realize the benefits that we hoped to receive as a result of the Share
Exchange, which include:
·
|
access to the capital markets of
the United States;
|
·
|
the increased market liquidity
expected to result from exchanging stock in a private company for
securities of a public
company;
|
·
|
the ability to use registered
securities to make acquisitions of assets or
businesses;
|
·
|
increased visibility in the
financial community;
|
·
|
enhanced access to the capital
markets;
|
·
|
improved transparency of
operations; and
|
·
|
perceived credibility and
enhanced corporate image of being a publicly traded
company.
|
There
can be no assurance that any of the anticipated benefits of the Share Exchange
will be realized in respect to our new business operations. In addition, the
attention and effort devoted to achieving the benefits of the Share Exchange and
attending to the obligations of being a public company, such as reporting
requirements and securities regulations, could significantly divert management's
attention from other important issues, which could materially and adversely
affect our operating results or stock price in the future.
45
COMPLIANCE
WITH CHANGING REGULATION OF CORPORATE GOVERNANCE AND PUBLIC DISCLOSURE WILL
RESULT IN ADDITIONAL EXPENSES.
Changing
laws, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act of 2002 and related SEC
regulations, have created uncertainty for public companies and significantly
increased the costs and risks associated with accessing the public markets and
public reporting. Our management team will need to invest significant management
time and financial resources to comply with both existing and evolving standards
for public companies, which will lead to increased general and administrative
expenses and a diversion of management time and attention from revenue
generating activities to compliance activities.
OUR
COMMON STOCK IS CONSIDERED A "PENNY STOCK," AND THEREBY IS SUBJECT TO ADDITIONAL
SALE AND TRADING REGULATIONS THAT MAY MAKE IT MORE DIFFICULT TO
SELL.
Our
common stock is currently considered to be a "penny stock" because it does not
qualify for one of the exemptions from the definition of "penny stock" under
Section 3a51-1 of the Securities Exchange Act for 1934, as amended (the
"Exchange Act"). Our common stock is considered a "penny stock" because it meets
one or more of the following conditions (i) the stock trades at a price less
than $5.00 per share; (ii) it is NOT traded on a "recognized" national exchange;
(iii) it is NOT quoted on the NASDAQ Capital Market, or even if so, has a price
less than $5.00 per share; or (iv) is issued by a company that has been in
business less than three years with net tangible assets less than $5
million.
The
principal result or effect of being designated a "penny stock" is that
securities broker-dealers participating in sales of our common stock will be
subject to the "penny stock" regulations set forth in Rules 15-2 through 15g-9
promulgated under the Exchange Act. For example, Rule 15g-2 requires
broker-dealers dealing in penny stocks to provide potential investors with a
document disclosing the risks of penny stocks and to obtain a manually signed
and dated written receipt of the document at least two business days before
effecting any transaction in a penny stock for the investor's account. Moreover,
Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any
investor for transactions in such stocks before selling any penny stock to that
investor. This procedure requires the broker-dealer to (i) obtain from the
investor information concerning his or her financial situation, investment
experience and investment objectives; (ii) reasonably determine, based on that
information, that transactions in penny stocks are suitable for the investor and
that the investor has sufficient knowledge and experience as to be reasonably
capable of evaluating the risks of penny stock transactions; (iii) provide the
investor with a written statement setting forth the basis on which the
broker-dealer made the determination in (ii) above; and (iv) receive a signed
and dated copy of such statement from the investor, confirming that it
accurately reflects the investor's financial situation, investment experience
and investment objectives. Compliance with these requirements may make it more
difficult and time consuming for holders of our common stock to resell their
shares to third parties or to otherwise dispose of them in the market or
otherwise.
WE
DO NOT FORESEE PAYING CASH DIVIDENDS IN THE FORESEEABLE FUTURE AND, AS A RESULT,
OUR INVESTORS' SOLE SOURCE OF GAIN, IF ANY, WILL DEPEND ON CAPITAL APPRECIATION,
IF ANY.
We
do not plan to declare or pay any cash dividends on our shares of common stock
in the foreseeable future and currently intend to retain any future earnings for
funding growth. As a result, investors should not rely on an investment in our
securities if they require the investment to produce dividend income. Capital
appreciation, if any, of our shares may be investors' sole source of gain for
the foreseeable future. Moreover, investors may not be able to resell their
shares of our common stock at or above the price they paid for
them.
Item
2. Unregistered Sale of Equity Securities and Use of Proceeds
Reference
is made to the Current Report on Form 8-K filed with the Securities Exchange
Commission on September 30, 2009.
Item 3. Default Upon Senior
Securities
Not
applicable.
46
Item
4. Submission of Matters to a Vote of Security Holders
Not
applicable.
Item 5. Other
Information
Not
applicable.
Item
6. Exhibits
The
following exhibits are included in this report or incorporated by reference into
this report:
Exhibit
|
||
Number
|
Description
|
|
31.1
|
Certification
of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K,
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.*
|
|
31.2
|
Certification
of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K,
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.*
|
|
32.1
|
Certification
of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.*
|
|
32.2
|
Certification
of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.*
|
* Filed
herewith.
47
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
CHINA
YONGXIN PHARMACEUTICALS INC.
|
||
Dated:
November 19, 2009
|
/s/ Yongxin
Liu
|
|
Yongxin
Liu
|
||
Chairman
of the Board and Chief Executive Officer
|
||
/s/ Yongkui
Liu
|
||
Yongkui
Liu
|
||
Chief
Financial Officer
|
48